



FOSUN PHARMA

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint st

Our Vision

We are committed to becoming a first-class enterprise in the global medical and healthcare market.

Our Mission

Better health for families worldwide.

Contents

02	Chairman's Report
04	Financial Highlights
05	Management Discussion and Analysis
48	Chairman's Report
56	Interim Condensed Consolidated Financial Statements
57	Interim Condensed Consolidated Financial Statements
58	Interim Condensed Consolidated Financial Statements
60	Interim Condensed Consolidated Financial Statements
62	Interim Condensed Consolidated Financial Statements
64	Notes to Interim Condensed Consolidated Financial Statements
99	Declarations

Directors

Executive Directors

Mr. Wu Yifang (吳以芳) (Chairman)
 Mr. Wang Kexin (王可心) (Co-Chairman)¹
 Mr. Guan Xiaohui (關曉暉) (Vice-Chairman)²
 Mr. Wen Dejun (文德鏞) (Chief Executive Officer)³

Non-executive Directors

Mr. Chen Qi (陳啟宇)
 Mr. Yao Fang (姚方)
 Mr. Xu Xiaoliang (徐曉亮)
 Mr. Pan Donghui (潘東輝)

Independent Non-executive Directors

Ms. Li Li (李玲)
 Mr. Tang Yuliang (湯谷良)
 Mr. Wang Quandi (王全弟)
 Mr. Yu Zhihan (余梓山)

Supervisors

Ms. Ren Jing (任倩) (Chairman)
 Mr. Cao Genxi (曹根興)
 Mr. Guan Yimin (管一民)

Joint Company Secretaries

Ms. Dong Xiaoli (董曉嫻)
 Ms. Gan Meigui (甘美霞)

Authorized Representatives

Mr. Wu Yifang (吳以芳)
 Ms. Gan Meigui (甘美霞)

Strategic Committee

Mr. Wu Yifang (吳以芳) (Chairman)⁴
 Mr. Chen Qi (陳啟宇)⁵
 Mr. Yao Fang (姚方)
 Mr. Xu Xiaoliang (徐曉亮)
 Ms. Li Li (李玲)

Audit Committee

Mr. Tang Yuliang (湯谷良) (Chairman)
 Mr. Wang Quandi (王全弟)
 Ms. Li Li (李玲)

Nomination Committee

Mr. Wang Quandi (王全弟) (Chairman)
 Ms. Li Li (李玲)
 Mr. Pan Donghui (潘東輝)

Remuneration and Appraisal Committee

Mr. Yu Zhihan (余梓山) (Chairman)
 Mr. Tang Yuliang (湯谷良)
 Mr. Wang Quandi (王全弟)
 Mr. Chen Qi (陳啟宇)
 Mr. Pan Donghui (潘東輝)

Environmental, Social and Governance Committee

Mr. Yu Zhihan (余梓山) (Chairman)
 Ms. Li Li (李玲)
 Mr. Wu Yifang (吳以芳)

Registered Office

9th Floor, No. 510 Caoa Road
 Didi
 Haihai, 200063, China

Principal Place of Business in the PRC

Bilibili A
 No. 1289 Haihai Road
 Haihai, 200233, China

¹ Mr. Wang Kexin was elected as a director of the Company on April 4, 2022.
² Mr. Guan Xiaohui was elected as a director of the Company on January 1, 2022.
³ Mr. Wen Dejun was elected as a director of the Company on April 4, 2022.
⁴ Mr. Wu Yifang was elected as a director of the Company on January 1, 2022.
⁵ Mr. Chen Qi was elected as a director of the Company on April 10, 2022.

⁴ Mr. Wu Yifang was elected as a director of the Company on January 1, 2022.
⁵ Mr. Chen Qi was elected as a director of the Company on January 1, 2022.

Principal Place of Business in Hong Kong

5/F, Main Building
348 King's Road
Hong Kong

Legal Advisers in Hong Kong

Ernst & Young

Legal Advisers in the PRC

Grall Law Firm (China)

Auditors

Ernst & Young
Certified Public Accountants
Registered Public Interest Entity Auditor
27th Floor, Main Building
979 King's Road
Hong Kong

Principal Banks

Hang Seng Bank Limited
China Development Bank
Industrial and Commercial Bank of China
Bank of China
China Min Sheng Bank
Hua Hai Development Bank

Corporate Name

China Fintech Development (Group) Company Limited*

Stock Abbreviation

FIN HA MA

Share Listing

A share: Hang Seng E share
Code: 600196
H share: Hang Seng E share
Code: 02196

A Share Registrar and Transfer Office in the PRC

China Resources Development & Clearing Company Limited
(C DCC) Hang Seng Branch
188 Bank of China Building
Hong Kong, China

H Share Registrar and Transfer Office in Hong Kong

First International Securities Limited
17/F, Far East Finance Centre
16 Harbour Road
Hong Kong

Corporate Website

http://www.fintechgroup.com

* The company is a public company under the Companies Ordinance of the Hong Kong.

Financial Highlights

For the six months ended 30 June

	2022 RMB million	2021 MB milli (in million)
Operating results		
Revenue	21,275	16,878
Gross profit	9,699	8,621
Profit from operations	1,999	1,343
Profit from operations after tax	2,379	3,304
Profit from operations after tax and minority interests	1,554	2,482
EBI/DA	3,881	4,670
Profitability		
Gross profit margin	45.59%	51.08%
Profit from operations margin	9.40%	7.96%
Net profit margin	8.79%	16.32%
Earnings per share (MB/da)		
Earnings per share after tax	0.60	0.97
Earnings per share after tax and minority interests	0.60	0.97
Of which: Pharmaceutical manufacturing segment		
Revenue	14,271	12,179
Gross profit	7,762	6,965
Profit from operations	1,890	1,353
Profit from operations after tax	1,579	1,257
Assets		
Assets	98,754	93,237
Equity	38,148	39,135
Liabilities	51,070	44,918
Capital	12,258	10,308
Debt-to-equity ratio	51.71%	48.18%

Management Discussion and Analysis

FINANCIAL REVIEW

During the reporting period, the Company's operating results are summarized in the following table:

During the reporting period, the Company's operating results are summarized in the following table:

Based on the Company's operating results for the reporting period, the Company's operating results are summarized in the following table:

The Company's operating results for the reporting period are summarized in the following table:

REVENUE

During the reporting period, the Company's operating results are summarized in the following table:

GROSS PROFIT

During the reporting period, the Gross Profit decreased 12.50% from MB9,699 million in 2020 to MB8,621 million in 2021. The decrease is mainly due to the following reasons: (1) the decrease in the sales volume of the main products; (2) the increase in the unit cost of the main products; (3) the increase in the unit cost of the main products. As a result, the Gross Profit margin decreased from 45.59% in 2020 to 5.49% in 2021. The Company will continue to optimize the production process and improve the product quality to reduce the unit cost and increase the Gross Profit.

SELLING AND DISTRIBUTION EXPENSES

During the reporting period, the Selling and Distribution Expenses decreased 1.07% from MB4,166 million in 2020 to MB4,211 million in 2021. The decrease is mainly due to the following reasons: (1) the decrease in the sales volume of the main products; (2) the decrease in the unit cost of the main products; (3) the decrease in the unit cost of the main products. As a result, the Selling and Distribution Expenses margin decreased from 19.58% in 2020 to 5.37% in 2021. The Company will continue to optimize the production process and improve the product quality to reduce the unit cost and increase the Gross Profit.

R&D EXPENSES AND R&D EXPENDITURE

During the reporting period, the R&D Expenses decreased 22.77% from MB2,399 million in 2020 to MB1,818 million in 2021. The decrease is mainly due to the following reasons: (1) the decrease in the sales volume of the main products; (2) the decrease in the unit cost of the main products; (3) the decrease in the unit cost of the main products. As a result, the R&D Expenses margin decreased from 16.39% in 2020 to 16.04% in 2021. The Company will continue to optimize the production process and improve the product quality to reduce the unit cost and increase the Gross Profit.

OTHER GAINS AND OTHER EXPENSES

During the reporting period, the Other Gains and Other Expenses decreased 60.43% from MB994 million in 2020 to MB651 million in 2021. The decrease is mainly due to the following reasons: (1) the decrease in the sales volume of the main products; (2) the decrease in the unit cost of the main products; (3) the decrease in the unit cost of the main products. As a result, the Other Gains and Other Expenses margin decreased from 60.43% in 2020 to 7.65% in 2021. The Company will continue to optimize the production process and improve the product quality to reduce the unit cost and increase the Gross Profit.

During the reporting period, the Other Gains and Other Expenses decreased 169.53% from MB573 million in 2020 to MB911 million in 2021. The decrease is mainly due to the following reasons: (1) the decrease in the sales volume of the main products; (2) the decrease in the unit cost of the main products; (3) the decrease in the unit cost of the main products. As a result, the Other Gains and Other Expenses margin decreased from 169.53% in 2020 to 7.65% in 2021. The Company will continue to optimize the production process and improve the product quality to reduce the unit cost and increase the Gross Profit.

SHARE OF PROFITS OF ASSOCIATES

During the reporting period, the share of profits of the Grantee is 2.92% of MB899 million for MB926 million for the reporting period 2021.

PROFIT FOR THE PERIOD

During the reporting period, the share of profits of the Grantee is 32.14% of MB1,869 million for MB2,754 million for the reporting period 2021. The share of profits of the Grantee is 8.79% and 16.32%, for the reporting period 2021.

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

During the reporting period, the Grantee is MB1,999 million, for the reporting period MB656 million. A share of profits of the Grantee is BN X million for the reporting period 2021, a share of profits of the Grantee is MB1 million. During the reporting period, a share of profits of the Grantee is MB1,567 million for the reporting period MB1,554 million for the reporting period 2021. The share of profits of the Grantee is 37.39%.

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

As at 30 June 2022, the total debt of the Grantee is MB30,461 million for MB25,299 million as at 31 December 2021. As at 30 June 2022, the total debt of the Grantee is 41.76% of the total assets, for the reporting period 3.43% of the total assets, for the reporting period 38.33% as at 31 December 2021. During the reporting period, the total debt of the Grantee is MB10,308 million as at 31 December 2021.

As at 30 June 2022, the total debt of the Grantee is MB8,698 million (31 December 2021: MB7,382 million) for the reporting period MB.

As at 30 June 2022, the total debt of the Grantee is MB4,928 million (31 December 2021: MB4,276 million).

Management

Discussion and Analysis

Unit: million CNY; Currency: MB

Cash and cash equivalents denominated in:	30 June 2022	31 December 2021
MB	7,330	6,032
HK dollar	1,721	1,615
US dollar	2,220	1,907
HK dollar	577	560
Other	156	78
Total	254	116
Total	12,258	10,308

Gearing Ratio

As at 30 June 2022, the gearing ratio, calculated as total liabilities less cash and cash equivalents divided by total assets, was 30.85%, as compared to 27.13% as at 31 December 2021.

Interest Rate

As at 30 June 2022, the average interest rate on the financial liabilities was 4.5% (31 December 2021: 4.2%).

Maturity Structure of Outstanding Debts

Unit: million CNY; Currency: MB

	30 June 2022	31 December 2021
Within 1 year	17,740	15,602
1 to 2 years	4,648	5,067
2 to 5 years	5,753	2,073
Over 5 years	2,320	2,557
Total	30,461	25,299

Available Facilities

A 30 J 2022, i e a h a a ala e MB12,258 illi , h e Gr ha iline a i a ilie
MB31,327 illi i a e a e h e Gr ha al e e i i a e e i h vari aj r a . A r i
t h a e e e t , h e a r a e h e Gr e al a i a ilie t r i a al e i e e t . h e ilia i
h a a ilie a e i h e a v al i i j al e t r h e a i a r a e i h a i e t la i . A
a 30 J 2022, t al a v ila e a i a ilie e r h e e arra e e t e a i a e MB57,845 illi i
a e a e hi h MB26,518 illi ha e e iline .

I April 2020, the C pa ai-e a val r the C C r the i rai a li i a r rae
 t ha MB5,000 illi t e i al i ve r. he a val ill e-e-e i ve t 31 Dec-e e 2022. I
 J I 2022 a A 2022, the C t e i ve i e r the NAFMII r he a-e-a e e i rai r the
 h t-e-e-e i al a MB6,000 illi a e i t-e MB4,000 illi the C , e e i ve
 he e i e e e i li i ill e-e-e i ve r t e-e-e i the a-e i a e e e e i e .

Collateral and Pledged Assets

A 30 June 2022, the Graha Lake Hillia lateral fractions (MB772 Hillia (31 Dec. 2021: MB550 Hillia) and MB772 Hillia (31 Dec. 2021: MB514 Hillia)).

A 30 J 2022, h. Gr. ha la h. l i a lla l a l l i : h. l e i v l e a i
MB100 illi (31 D. 2021: MB69 illi) a h. l e i v l e a i MB8 illi (31 D. 2021:
MB8 illi).

A 30 June 2022, 12:00 UTC. The image shows a satellite view of a coastal region, likely the Gulf of Mexico, with a color scale indicating temperature or salinity. The scale ranges from 20 to 30. The image is labeled "A" and "30 June 2022, 12:00 UTC". The image is also labeled "MB8" and "illi".

A la 30 de Iunie 2022, în Grădina de lemn în Iliria s-a înregistrat: 58.67% în înflorire și în fructificare.

D.ail h e lla c e r a l a b e e a a r e i 16 h e i a i a l a e e .

Cash Flow

he a h t he Gr i ai l e r egi aial ke ite t e, t e i i t e t a ri i al e t e a i t
r ha e a aial e i t e, a i r ha e a i aillie a i e t he Gr t he a le el
h t he a h l t he Gr e e e a e r (t e i) e a i a i i l l e, i e t a i i l l e a i a i a i i l l e r
he e e i e ri a t he ite i ri 2021.

Management

Discussion and Analysis

Unit: million RMB

	January – June 2022	January – June 2021
Net cash provided by operating activities	1,820	1,707
Net cash used in investing activities	(2,485)	(2,450)
Net cash provided by financing activities	2,420	770
Net change in cash and cash equivalents	1,755	27
Cash and cash equivalents at the beginning of the year	6,451	7,325
Cash and cash equivalents at the end of the year	8,274	7,248

Capital Commitments and Capital Expenditures

During the reporting period, capital expenditures were RMB2,174 million, which mainly included the purchase of property, plant and equipment, the purchase of intangible assets, the purchase of subsidiaries and the purchase of other long-term assets. Details of capital expenditures are as follows:

As at 30 June 2022, the Group has capital commitments of RMB5,416 million, which mainly included the purchase of property, plant and equipment, the purchase of intangible assets, the purchase of subsidiaries and the purchase of other long-term assets. Details of capital commitments are as follows:

Contingent Liabilities

As at 30 June 2022, the Group does not have any contingent liabilities.

Interest Coverage

During the reporting period, the interest coverage ratio was 8.30 times (reference ratio in 2021: 10.91 times). The interest coverage ratio was calculated as follows: Interest Coverage Ratio = EBITDA / Interest Expense. In 2021, the interest coverage ratio was 10.91 times, which was mainly due to the increase in EBITDA and the decrease in interest expense. In 2022, the interest coverage ratio was 8.30 times, which was mainly due to the decrease in EBITDA and the increase in interest expense.

RISK MANAGEMENT

Foreign Currency Exposure

The Group has no significant foreign currency exposure. The Group's assets and liabilities are denominated in Hong Kong dollars, which are the functional currencies of the Group's operations.

Interest Rate Exposure

The Group's interest rate exposure is primarily related to its bank borrowings. The Group's interest rate risk is managed through the use of fixed-rate and floating-rate debt instruments.

BUSINESS REVIEW

1. The Board's Discussion and Analysis on Operations of the Group for the Reporting Period

During the reporting period, the Group's operations were affected by the COVID-19 pandemic, which led to a significant decline in demand for its products and services. The Group's revenue decreased by 15.2% compared to the same period of the previous year. The Group's operating profit decreased by 28.5% compared to the same period of the previous year. The Group's net profit decreased by 32.1% compared to the same period of the previous year. The Group's cash and cash equivalents decreased by 10.3% compared to the same period of the previous year. The Group's total assets decreased by 8.7% compared to the same period of the previous year. The Group's total liabilities decreased by 5.4% compared to the same period of the previous year. The Group's equity decreased by 12.6% compared to the same period of the previous year.

During the reporting period, the Group's operations were affected by the COVID-19 pandemic, which led to a significant decline in demand for its products and services. The Group's revenue decreased by 15.2% compared to the same period of the previous year. The Group's operating profit decreased by 28.5% compared to the same period of the previous year. The Group's net profit decreased by 32.1% compared to the same period of the previous year. The Group's cash and cash equivalents decreased by 10.3% compared to the same period of the previous year. The Group's total assets decreased by 8.7% compared to the same period of the previous year. The Group's total liabilities decreased by 5.4% compared to the same period of the previous year. The Group's equity decreased by 12.6% compared to the same period of the previous year.

The Group's operations were affected by the COVID-19 pandemic, which led to a significant decline in demand for its products and services. The Group's revenue decreased by 15.2% compared to the same period of the previous year. The Group's operating profit decreased by 28.5% compared to the same period of the previous year. The Group's net profit decreased by 32.1% compared to the same period of the previous year. The Group's cash and cash equivalents decreased by 10.3% compared to the same period of the previous year. The Group's total assets decreased by 8.7% compared to the same period of the previous year. The Group's total liabilities decreased by 5.4% compared to the same period of the previous year. The Group's equity decreased by 12.6% compared to the same period of the previous year.

Di cosa si parla?

D r i h e e r i e r i h e e r i e r i h e G r a a l l :

 i: illi C rre : MB

	Revenue Jan – Jun 2022		Jan – Jun 2021		Change (%)
	Amount	Percentage of revenue (%)	Amount	Percentage of revenue (%)	Change (%)
By business segment					
Pharmaceutical activities	14,271	67.08	12,179	72.16	17.18
Medical devices activities	4,035	18.97	2,832	16.78	42.48
Healthcare services	2,917	13.71	1,843	10.92	58.27
By geographical locations					
China Mainland	13,683	64.31	11,680	69.20	17.15
Outside China Mainland	7,592	35.69	5,198	30.80	46.06

Main Operational Progress of the Group during the Reporting Period

[illegible]

A a h e a e h i t e n t h e r t e i r a i a n n i a i t h e e i i a i (a - a l l e l l i a e r (N C L C)) , h e h i r i i a i (e e i e t a e a l l e l l a e r (E - C L C)) a h e t h i i a i (e h a e a l a e l l a r i a (E C C)) H a i h a i C h i e e M a i l a h a e a e e a e e r a a l l . H a i h a i r h e t e a e t a l l e l l a e r (C L C) h a a l e e r a e e r h a D r D e i a i h e . . F D A . D r i h e e n t i e r i , F - 1 5 0 2 r h e t e a e t a l l e l l a e r (N C L C) e a h a e l l i a l i C h i e e M a i l a . F - 1 5 0 2 i e t h e h e l l i a a / r h e h e r a n t h e t e a e t a l l e l l a e r H E 2 e e i a v a e a r i a e r i C h i e e M a i l a h a e e a n n i a e r h a e l l i a l r i a l . F C N - 1 5 9 r h e t e a e t h i i i t r a a e r i v e a l r a i h a e e a n n i a e r i h a e l l i a l r i a l i C h i e e M a i l a , t e n t i v e . h e j i t v e t e F K i e ' e C A - e l l h e r a n n i a e r , F K C 8 8 9 (r h e t e a e t a l l e l l a e r i h e l a e e r t e r a r t a l e l l i h a (r r M C L) a e r i r e - l i e a h i h e r e i h e r a n) , a a n n i a e r i l i a l r i a l i C h i e e M a i l a . e i a r i r l a i C i r a (N A C I D - 1 9 v a i e) a a n n i a e r v a i a i r h i l t e a e 5 1 1 i M a a a i a , C h i a i A n i l a M a 2 0 2 2 e i v e l (v a i a i i a a e r r h i l t e a e 6 h 4 a a n n i a e r i A 2 0 2 2 i a i a , C h i a) . I A n i l 2 0 2 2 , h e G r h e l - e v e l C I D - 1 9 a i e t e t e t e a n n i a e r v e r l a h i C h i e e M a i l a . I a i i , i J l 2 0 2 2 , r i i a r F h a r a e t a l l r i a l a G e i e B i t e h e t e i t a a t e e e i t e l a i t h e t r a e i r a i , a h e r h i , h e j i t e v e l h e t a F h a r a e t a l l r i a l e l i v e e r i a l i a i A n i l h e e n n i a e r i l e h e t e a e t a n n i a e r i C I D - 1 9 a A I D . h e A n i l e a l e , i e n n e e l e v e l h e C h i a , i h e i t a l l e l a r r a l e i a i r C I D - 1 9 a n n i a e r r l a h .

D r i h e e n t i e r i , 2 i v a i v e r (i i a i) a 1 0 e e r i r (i i a i) h e G r h a v e e e a n n i a e r r l a h i C h i e e M a i l a / h e . . 1 i v a i v e r (i i a i) a 1 8 e e r i r (i i a i) h a v e e e a n n i a e r r l a h (N D A) i C h i e e M a i l a . 1 4 i v a i v e r (i i a i) a 9 e e r i r (i i a i) h a v e e e a n n i a e r r l i a l r i a l (I N D) i C h i e e M a i l a .

F r a i l h e & D a l a h h e G r a j r i v a i v e r (i i a i) r i h e e n t i e r i , h e a e t e e t a l e 1 t a l e 3 .

Table 1 — Innovative drugs approved for launch during the Reporting Period

No.	Name of drugs	Classification of registration	Indications	Remarks
1	Ha i h a (e r l i a i j e i)	h e r a e i i l i a l r i a l	M i r a e l l i e i a i l i - h i h (M I - H) l i t r	A n n i a e r i i a l a r e i
2	Ha Li Ka (r i i a i j e i)	h e r a e i i l i a l r i a l	h e a i A r h r i (A)	/

Table 2 — Innovative drugs applied for launch during the Reporting Period

No.	Name of drugs	Classification of registration	Indications
1	Ha i h a (e r l i a i j e i)	h e r a e i i l i a l r i a l	I i a i i h h e h e r a n (a r h a i a e n n i a e r) r h e i r - l i e t e a e t e e i v e a e a l l e l l a e r (E - C L C)

Table 3 — Innovative drugs that obtained clinical approvals during the Reporting Period

[illegible]

Note: r F K_i a j i v i e i e

- D ri t he r e n t i e r i , h e G r u e i a l e j e a e i a l i a i i e i l t e h e e
i e n e e t m e f a i a a l l i . h e e i a l e j e e e e i a l l r e h t e a j r t e i e e , a e l ,
e i a l e l , t e n i r a t h a l h a e i a l e l a t e . i r a M e i a l , h e t e l a t r e i a l
e l , i e t e e i l a l h a e l a a l l i a t h e t e h e e i l a l i k e a l a t .
D ri t he r e n t i e r i , h e r e n t i i t e a l e k e v e e t h e r i k e a t a n y i a e l 65% . h e
e i a l i a i e e t t h e i e l e e n e r a i a l i e r a i , i l i n e h e & D a
a a r i a a l l i e i a i i r e t , a e n e i t e i e a t a i l i t r , i e i
a e a l l i , e k e t - a r i v a t a r , t e n t i v e e r a l e r v e a i e i , a a i i e t r,
e i a e h l i a l i v a r i v i a i l i . D ri t he r e n t i e r i , l e i a i e t a t r ,
l i a l h e i t a i a a i e r a e a a l m e r a t h e r i a t i i t r e t e k e l a h e e i e l .

Table 1: Major therapeutic area breakdown of sales by quarter. The table shows sales in million RMB for the first six quarters of 2022 compared to the same period in 2021. The data is categorized by major therapeutic area.

Unit: million RMB

Major therapeutic area	Jan – Jun 2022	Jan – Jun 2021*	Change (%)
Major therapeutic area 1 (Notes 1, 7)	2,550	1,705	49.56
Major therapeutic area 2 (Notes 2, 7)	3,629	2,656	36.63
Major therapeutic area 3 (Notes 3, 7)	1,383	1,419	2.54
Major therapeutic area 4 (Notes 4, 7)	1,095	1,019	7.46
Major therapeutic area 5 (Notes 5, 7)	422	616	31.49
Major therapeutic area 6 (Notes 6, 7)	633	577	9.71

Note 1: Major therapeutic area 1 sales increased by 49.56% compared to the same period in 2021, primarily driven by the growth of sales for Ha Li Ka (利卡), Ha Li Ka (利卡), and Ke Xi (可西).

Note 2: Major therapeutic area 2 sales increased by 36.63% compared to the same period in 2021, primarily driven by the growth of sales for C ir a (C ir a) and Ha Li Ka (利卡).

Note 3: Major therapeutic area 3 sales increased by 2.54% compared to the same period in 2021, primarily driven by the growth of sales for Ha Li Ka (利卡) and Ke Xi (可西).

Note 4: Major therapeutic area 4 sales increased by 7.46% compared to the same period in 2021, primarily driven by the growth of sales for Ha Li Ka (利卡) and Ke Xi (可西).

Note 5: Major therapeutic area 5 sales increased by 31.49% compared to the same period in 2021, primarily driven by the growth of sales for Ha Li Ka (利卡) and Ke Xi (可西).

Note 6: Major therapeutic area 6 sales increased by 9.71% compared to the same period in 2021, primarily driven by the growth of sales for Ha Li Ka (利卡) and Ke Xi (可西).

Note 7: Major therapeutic area 7 sales increased by 9.71% compared to the same period in 2021, primarily driven by the growth of sales for Ha Li Ka (利卡) and Ke Xi (可西).

Major therapeutic area 7 sales increased by 9.71% compared to the same period in 2021, primarily driven by the growth of sales for Ha Li Ka (利卡) and Ke Xi (可西).

Di cosa Aali

Ma j i t A l a i e i a e t i e i a i a i e i e , t a e a i a i , l e p a i l e h t h l i e a l i a i

* h₂ a₂ r̄ Ja ar̄ J 2021 a t₂ a₂ a r̄ i t₂ h₂ a₂ Ja ar̄ J 2022, h₂ a₂ r̄ Ja ar̄ J 2021
i l t₂ a₂ t₂ e₂ e₂ a Ji (e₂ l i l i a l₂) h i h e a e a t₂ a j r̄ t₂ a e l t₂ a₂ t₂ e₂ e₂ h i Li Da
(a l i j e e i l a₂ a l₂) H a h₂ h a r̄ a h i h a l₂ e r̄ i h₂ e e r̄ i e r̄ i .

Important events

- *Progress of PD-1 inhibitor Han Si Zhuang (serplulimab injection)*

1. Mar h 2022, h e i r i i a i (t h e t a e t i i t a l l i e i a i l i - h i h (M I - H) l i t h e
 i a i v e D - 1 i h i t H a i h a (t h l i a i j e t i) i e r e t e t e v e l h e G r t a a n n t e
 h e N M A r i i a l a r e i . h e i i a i a t e e t a e i i M I - H r a r e r ,
 t r i a i e t a e a i e t r . A a 26 A 2022, H a i h a (t h l i a i j e t i)
 l i e i i i 18 j e t i C h i a .

A $\frac{1}{2}$ he a $\frac{1}{2}$ hi $\frac{1}{2}$ he NDA $\frac{1}{2}$ he $\frac{1}{2}$ i $\frac{1}{2}$ i $\frac{1}{2}$ ($\frac{1}{2}$ - all $\frac{1}{2}$ $\frac{1}{2}$ a $\frac{1}{2}$ (N CLC)),
 he $\frac{1}{2}$ hi $\frac{1}{2}$ i $\frac{1}{2}$ i $\frac{1}{2}$ ($\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ a $\frac{1}{2}$ all $\frac{1}{2}$ $\frac{1}{2}$ a $\frac{1}{2}$ (E - CLC)) a $\frac{1}{2}$ he $\frac{1}{2}$ hi $\frac{1}{2}$ i $\frac{1}{2}$ i $\frac{1}{2}$ ($\frac{1}{2}$ ha $\frac{1}{2}$ a
 $\frac{1}{2}$ $\frac{1}{2}$ a $\frac{1}{2}$ (E CC)) Ha $\frac{1}{2}$ i h a $\frac{1}{2}$ ($\frac{1}{2}$ $\frac{1}{2}$ li a $\frac{1}{2}$ i $\frac{1}{2}$ j e $\frac{1}{2}$ i) i Chi $\frac{1}{2}$ e $\frac{1}{2}$ Mai la $\frac{1}{2}$ $\frac{1}{2}$ e $\frac{1}{2}$ e $\frac{1}{2}$ e $\frac{1}{2}$ i $\frac{1}{2}$ v e l , a
 Ha $\frac{1}{2}$ i h a $\frac{1}{2}$ ($\frac{1}{2}$ $\frac{1}{2}$ li a $\frac{1}{2}$ i $\frac{1}{2}$ j e $\frac{1}{2}$ i) $\frac{1}{2}$ he $\frac{1}{2}$ e a $\frac{1}{2}$ e $\frac{1}{2}$ all $\frac{1}{2}$ $\frac{1}{2}$ a $\frac{1}{2}$ (CLC) a al $\frac{1}{2}$ r a $\frac{1}{2}$ e $\frac{1}{2}$ r ha
 Dr $\frac{1}{2}$ D e i a i $\frac{1}{2}$ h e . FDA. I $\frac{1}{2}$ a $\frac{1}{2}$ i la $\frac{1}{2}$ i $\frac{1}{2}$ h e i $\frac{1}{2}$ e r i a al i $\frac{1}{2}$ h e r a $\frac{1}{2}$ i e , $\frac{1}{2}$ e li $\frac{1}{2}$ i $\frac{1}{2}$ e r a i al
 $\frac{1}{2}$ i $\frac{1}{2}$ e $\frac{1}{2}$ r ha $\frac{1}{2}$ e ll li al $\frac{1}{2}$ he $\frac{1}{2}$ hi $\frac{1}{2}$ i $\frac{1}{2}$ i $\frac{1}{2}$ i $\frac{1}{2}$ ($\frac{1}{2}$ $\frac{1}{2}$ $\frac{1}{2}$ a $\frac{1}{2}$ all $\frac{1}{2}$ $\frac{1}{2}$ a $\frac{1}{2}$ (E - CLC)), he
 $\frac{1}{2}$ i a i $\frac{1}{2}$ h e r a $\frac{1}{2}$ h a $\frac{1}{2}$ h e r i a r $\frac{1}{2}$ e $\frac{1}{2}$ i $\frac{1}{2}$ v e r a l l $\frac{1}{2}$ r $\frac{1}{2}$ v a l ($\frac{1}{2}$), a a $\frac{1}{2}$ e $\frac{1}{2}$ e $\frac{1}{2}$ h e l $\frac{1}{2}$ e $\frac{1}{2}$ e $\frac{1}{2}$ D a a
 M $\frac{1}{2}$ i $\frac{1}{2}$ r i C $\frac{1}{2}$ i $\frac{1}{2}$ e e (IDMC). he $\frac{1}{2}$ e i a $\frac{1}{2}$ i $\frac{1}{2}$ h e t al $\frac{1}{2}$ h e la i $\frac{1}{2}$ h e e r a l li a $\frac{1}{2}$ r $\frac{1}{2}$ h a $\frac{1}{2}$ h e h a e
 $\frac{1}{2}$ r $\frac{1}{2}$ a 15.4 $\frac{1}{2}$ h a 10.9 $\frac{1}{2}$ h , $\frac{1}{2}$ e $\frac{1}{2}$ i $\frac{1}{2}$ v e l , a $\frac{1}{2}$ h e 24- $\frac{1}{2}$ h v e r a l l $\frac{1}{2}$ r $\frac{1}{2}$ v a l r a e $\frac{1}{2}$ e 43.1% a $\frac{1}{2}$ 7.9%,
 e $\frac{1}{2}$ e i $\frac{1}{2}$ v e l .

A a h e a e h i t e r , H a i h a (- e r l i a i j e i) i i a i i h H L X 0 7 (t e i a a i -
EGF h a l e l a l a i i j e i) a H a B e i a i (- e a i n a i j e i) r h e i r - l i - e t a - e t
t e - e a l e r - a a i h e a e l l a r a r i a (H C C) t e - e i v e a n n u a l r h a e l l i a l t r i a l i C h i - e -
M a i l a . h e h a e l l i a l H a i h a (- e r l i a i j e i) i i a i i h h e h e r a
(i a i + 5 - E) r h e i r - l i - e t a - e a i e i h l a l a v a - e r - a a i - e h a - e a l a e l l
a r i a (E C C) h a - e t h e - r i a r - e i t e i - t e e r j a l (F) a v e r a l l r j a l () i a
i - e r i a a l i , a a - e - e h e l - e - e D a a M i r i C i - e e (I D M C) .

Ba le t h e i - t e i a e - e v e l t t r a e C + G l a l (i a i h e a + l a l i a i) , H a i
 h a (- t l i a i j e i) h a - e a t t e r l i i a l t r i a l i C h i a , t h e , h e E s a h e r r i e /
 t e i . A a h e a e t h i k e t , 11 i a i h e r a i e - t e e H a i h a (- t l i a i j e i) a e
 - t i l i i a l t r i a l i v a r i t r i e a t e i a r t h e r l .

• Progress of CAR-T cell therapy products

▲ Kai Da (吉利) i he ir t he j i t ve t e F K t e a h r i m e a r t h e m f l a l i n e m f i i C h i a t l l i t h e t e h t r a e r t e a r a , a C A - e l l h e r a m f t t h e m f K t e h a r a . ▲ Kai Da a a m f v e r l a h i C h i e M a i l a i J e 2021, e i h e i r t C A - e l l h e r a m f a m f v e r t e i l a h . l i e t h e t e a e t a l p a i e t i h t e l a m e r t e r a t t l a r e B - e l l m f h a (t / t D L B C L) a e r m f i r e - l i e r h i h e r t e i h e r a m f . A a h e e J I 2022, ▲ Kai Da h a e e i l e i h e r a i m e e r i a l h e a l h i r a e 44 m f j e a i i p a l i e a v e r 50 e r i a l i r a e , h i l e h e e r t e a t e t e e r t e r h a t e a h e e a r l 100 .

h e e i i a i ▲ Kai Da (t h e t e a e t a l p a i e t i h t e l a m e r t e r a t t i e r t - H i l m f h a (t / t I N H L) a i i l l i l a r l m f a a a r i a l m e l m f h a) t e e v e a m f v a l r l i i a l r i a l i C h i e M a i l a a t a a l i l e i h e t e a h r h h e r a m f r m f r a i 2021 . A a h e e t h e e r t i e r i , h e i i a i h a e t e t e h e l i i a l r i a l a e i C h i e M a i l a .

h e h i r i i a i ▲ Kai Da (t h e t e a e t a l p a i e t i h l a r e B - e l l m f h a (t / t L B C L) h a i t e r a t t i r - l i e i h e h e r a m f r h a t e l a m e r t h i 12 h i r - l i e i h e h e r a m f) t e e v e a m f v a l r l i i a l r i a l i C h i e M a i l a i A t 2022 . I A p r i l 2022, e a r a t e e v e a m f v a l r l a h r t h e . F D A t h e a v e e i e i a i , e i h e i r C A - r i h e r l t e e v e . F D A a m f v a l a a e - l i e h e r a m f r L B C L . h e l e r l l - m f t e l e a r a , m a - 1 h h a h e 5 - e a r v e r a l l r j v a l () r a e t e l a m e r t e r a t t L B C L p a i e t t e a e i h e a r a t e a h e 42.6% , a h e 5 - e a r v e r a l l r j v a l r a e C p a i e t t e a h e 64.4% . h e a a ▲ Kai Da, e a r a a h e i r t e a l r l t e a t e h i h l i i l a r i t e r a a e e i v e e , h i t h e i i a i m f v e e t t h e t e m e r a e a v e r a l l r j v a l m f i p a i e t .

I a i i , F K t e ' e C A - e l l h e r a m f F K C 889 t e e v e a m f v a l r l i i a l r i a l i C h i e M a i l a i M a r h 2022 t h e t e a e t a l p a i e t i h t e l a m e r t e r a t t a l e e l l m f h a (t / t M C L) a e r m f i r e - l i e r h i h e r t e i h e r a m f . A a h e e h e e r t i e r i , h e i i a i h a e t e t e h e l i i a l r i a l a e i C h i e M a i l a .

• Cooperation on the joint development and exclusive commercialization of Azvudine

I J I 2022, t i a r F h a r a e i a l l r i a l a G e i e B i v e h e t e i t a a t e e e i t e l a i t h e r a e i m f a i , a h e r h i , h e j i t e v e l m e t a F h a r a e t a l I r i a l e l i v e e r i a l i a i A m v i e h e t m f a i l e h e t e a e t a m f e v e i N v e l C r a j r (2019 - C) a t A I D . h e A m v i e a l a , l e n e e l e v e l m f C h i a , i h e i r t a l l l e l a r r a l e i a i r C I D - 19 a m f v e r l a h . 25 J I 2022, h e r a i e h e e e r t e i i a l a m f v a l r h e N M A r e i t e a e t a l p a i e t e r i e r a e C I D - 19 . t e j l , A m v i e a l a a i e h e i i a l a m f v a l r h e N M A r e i i a i t h h e r t e v e r t r a r i a e i h i t t h e t e a e t a l H I - 1 i e t e p a i e t (i e A I D p a i e t) t h h i h j r a l a .

9 A 2022, A m v i e a l a t e i l e i h e D i a i a t e a e t G i e l i e r C I D - 19 (9 h E i i) (《 新 型 冠 状 病 毒 肺 炎 診 療 方 案 (第 九 版) 》) . A a h e a e h i t e n t , A m v i e a l a h a v e e e i t e i m f t e e t m f t e i a l i r a e e i G a , H e a , H a i a , J i l i , H a i j i a a G a a h e r m f j e a i l e . F h a r a e i a l l r i a l h a e t e i t a r a e i m f a i a t e e t i h i h a r , a l e a i h a r a e i a l i r i i e t e r m f i e i C h i a , t e h a e h e t e r i a l a e i i l l A m v i e a l a , a a t e l a e t h e a i a l h a e l a r v e r a e . A a h e a e h i t e n t , A m v i e a l a h a v e e e e i v e l h i m f X i j i a , H a i a , H e a a h e r m f j e a i l e , t r i i t t h e C I D - 19 m f e v e t a t l .

- Other license-in and license-out projects

On 1 July 2022, the Company entered into a license-in agreement with the Licensor, a subsidiary of the Licensor's parent company, for the license-in of the Licensor's intellectual property rights related to the development and commercialization of a certain drug. The license-in agreement has a term of 20 years, starting from the date of the license-in agreement. The Company has paid a license fee of RMB 10 million to the Licensor. The Company will be responsible for the development and commercialization of the drug. The license-in agreement is subject to the approval of the relevant regulatory authorities. The Company has obtained the necessary approvals from the relevant regulatory authorities. The license-in agreement is expected to generate significant economic benefits for the Company in the future.

On 1 July 2022, the Company entered into a license-out agreement with the Licensee, a subsidiary of the Licensee's parent company, for the license-out of the Company's intellectual property rights related to the development and commercialization of a certain drug. The license-out agreement has a term of 20 years, starting from the date of the license-out agreement. The Company has received a license fee of RMB 10 million from the Licensee. The Licensee will be responsible for the development and commercialization of the drug. The license-out agreement is subject to the approval of the relevant regulatory authorities. The Company has obtained the necessary approvals from the relevant regulatory authorities. The license-out agreement is expected to generate significant economic benefits for the Company in the future.

On 1 July 2022, the Company entered into a license-in agreement with the Licensor, a subsidiary of the Licensor's parent company, for the license-in of the Licensor's intellectual property rights related to the development and commercialization of a certain drug. The license-in agreement has a term of 20 years, starting from the date of the license-in agreement. The Company has paid a license fee of RMB 10 million to the Licensor. The Company will be responsible for the development and commercialization of the drug. The license-in agreement is subject to the approval of the relevant regulatory authorities. The Company has obtained the necessary approvals from the relevant regulatory authorities. The license-in agreement is expected to generate significant economic benefits for the Company in the future.

On 1 July 2022, the Company entered into a license-out agreement with the Licensee, a subsidiary of the Licensee's parent company, for the license-out of the Company's intellectual property rights related to the development and commercialization of a certain drug. The license-out agreement has a term of 20 years, starting from the date of the license-out agreement. The Company has received a license fee of RMB 10 million from the Licensee. The Licensee will be responsible for the development and commercialization of the drug. The license-out agreement is subject to the approval of the relevant regulatory authorities. The Company has obtained the necessary approvals from the relevant regulatory authorities. The license-out agreement is expected to generate significant economic benefits for the Company in the future.

- *Deepening of global operation*

h r h a r a r - l i l a l l a t h e G r h a h e l i i a r r e a l a l m r a i t e r r i i & D, m i a e r i a l i a i . A h e a e i h e G r i l l i e t h e h e r i i l a l i i a l e t a e i r h i h m e i a l a l e t h l a l j i . A a h e e h e e m i e r i , h e t a l e r v e a e m e e t e h e 6,099, a i r 16.7% h e G r m t a l e m e e .

I h e a r h e G r t e h e e r a i a i a l e t e a t i r h e e h e a a t e r i t h e i e a e , a i e t a i v e l e e t r a e i m r a i a r h e r a m i a t e a a h . A a t h e e h e e m i e r i , h e G r h a l a h e 22 r e r i t r a , i l i m r a i e a 2 e i t r 2019- C i h e i e a e , m r a e i h 5 a j r i r i r a 16 r m r h a i r a i a t (G) , v e t h e t a i l h a i h a r a h r h 21 h a e l m j e t , a e e e i t a t a l e a r l 20 m r a i a t e e t t v e r 85% t h e i e r a e r i r i i t e (I D N) , t h e e r i a l i h a e l a r v e a e .

I e e r i a r h a A r i a , h e G r h a e 5 t e i a l i r i i e e e r , i h a e a a 800 r l i e a l e m e e a l i h e a e v e l e t e i a l a a e e t a a i l i e , e r m r a i a a i l i e a B2B2C e r j e a a i l i e , a m j e a e e e j e t e i r a i , i r l a i , a a e i m t i a m l a h a a a l e t a h e r e j e , h i h l a i a l i a i t h e G r m m t a e a a r a i . D r i h e e m i e r i , h e i r i i e e e r i C t e l v i e e A r i a e e m r a i , h i h i t e l h e l a r e l a l i r i i e e e r i h e f t e h m a i t e i e t A r i a . h e i r i i e e e r i K e a m e h e i e i m e i h e l e t a i a l e C r (I C C) a e a e i a l i e t m l i e . h e G r h a e e a i i i h e a i - a l a r i a l r l a l l v e r h e e a r . D r i h e e m i e r i , A r e h e r l e a r i e a l e (m a r e h e r a l e) h a v e a i e H - e r i i a i . I J I 2022, h e r i i m h a e l l h e G r i e l l i e t m a e t a i a l a r i a l r e e e m e m i t h e m i a a i a r e r i e t t i l a i e t a i a l a r t a a r i a a t i h h i h a l i t , l a a t e l i v e r .

e l i h e G r m i e t a i a l m i a a r a a l i e e e r i a i , t h e r i h v e a m t a e a a r a i a a i l i e , i J a a r a M a r h 2022, r i i a r F h a r a e i a l l r i a l a l i e e t a a t e a m l h e e e r i v e r i M l m r a j r , a C I D - 19 r a l r M e r , a N i r a t e l j r , a C I D - 19 r a l r i m e r , a a i a i N i r a t e l j r i t a j r M r e t a i i - a l i e e t r i e i h e r l . h e l i e e a l l t h e m t i t h e a i v e h a r a e i a l i t e i e t a h e i i h e r .

R&D innovation

L e v e r a i h e l a l & D e e e r , h e G r m r i a e m j e t e a l i h e a a e e t a e l l a m j e t a a e e t , m i r i m e h e m i r a e i m j e t h e e l a l l i a l a t e i r a i a a i l i e , a i m v e & D e i e . A h e a e t L e v e r a i t h e e t e i l a l i e e v e l m e t (B D) e a , h e G r h a a e t t e a l m t a e h l m a r i h e i r r e i a l i a i . h r h i e m e e t & D , m r a i v e e v e l m e t l i e e i r i a i - e e h i a l , h e G r h a l l a r e a l l t e l e i v a i v e r , a i r a e l l h e r a m t e h l m a r e e e r i t r a i e l a i , e a l i a a l i e a r e e , e r a l e r v e a h e r a j r h e r a m i a t e a , a a i v e l m t e t e h t i e , h a N A , e e h e r a m , A D C a r t a , t e h a e l t e & D a a i l i e .

A a h e e h e e m i e r i , h e e e e v e r 260 m l i e m j e t h e G r m i v a i v e r , i i i l a r , e e r i r a t i e e a l a i i e (r h e a i l h e a j r m l i e r m j e t , m a e e e e t a l e 4) . D r i h e e m i e r i , a t a l 51 m e h a e e a m l e r i h e h a r a e i a l a a r i e e t h e G r m i l i 6 . m e t a m l i a i , 6 C a m l i a i , i h 26 l i e e i v e t m e t t a i e .

Table 4 — Major pipeline drug projects

Type	Number (calculated according to indications)	Remarks
Innovative drugs	70	/
1.1.1: All Le lar i vative r e f i e n e c e t e v e l h e t	22	F r a i l h e a j r i e e r l i a l a a n n i a i r a l e , a e e e e t a l e 5. C t r i i 3 i e e r h a e l l i a l r i a l .
Bi h a r a e i a l i v a t i v e r i e n e c e t e v e l h e t	32	F r a i l h e a j r i e e r l i a l a a n n i a i r a l e , a e e e e t a l e 6. C t r i i 2 i e e r a n n i a i r a l e a 8 i e e r h a e l l i a l r i a l .
L i e e i i v a t i v e r	16	F r a i l , a e e e e t a l e 7. C t r i i 1 i e e r a n n i a i r a l e a 6 i e e r h a e l l i a l r i a l .
Biosimilars under independent development	13	F r a i l , a e e e e t a l e 8. C t r i i 2 i e a n n i a i r a l e h , 1 i e e r a n n i a i r a l e a 4 i e e r h a e l l i a l r i a l .
Generic drugs	130	/
1.1.1: I n t e r e f i r	14	/
Consistency evaluation items	23	/

Note 1: h i a l e e i l e h e n n i e r n e t G l a h a r a .

Note 2: h i a l e e i l e h e C D 1 9 - a r e a t I C A - e l l h e r a n n i F K C 8 8 9 F K i e a j i v e t o h i h i e r h e
t e a t e t a t n e t i h t e l a n e t e r a t r a l e e l l I h a (t r M C L) a e r n i r e - l i e r h i h e t e i h e r a n n i a h a
e e a n n i a i r a l i a l r i a l i C h i e e M a i l a . A a t h e e t h e e n n i e r i , h i i a i h a e e e t h e l i a l r i a l
a e i C h i e e M a i l a .

Table 5 — Small molecular innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese Mainland as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
1	Anti-tumor	FCN-338	Hepatocellular carcinoma	Phase I clinical trial	Phase I clinical trial (in Hong Kong)
2			Advanced gastric cancer B-line item	Phase I clinical trial	
3		FCN-159	Malignant melanoma	Phase I clinical trial	
4			Neuroendocrine tumor	Phase II clinical trial (in Europe and Latin America)	
5			Lung cancer	Phase I clinical trial	
6			Histiocytosis	Phase II clinical trial	
7		IN1001	Liver cancer	Phase I clinical trial	Phase I clinical trial (in Hong Kong)
8		AF-189	Non-small cell lung cancer (1+)	Phase II clinical trial	Phase I clinical trial (in Hong Kong)
9			Non-small cell lung cancer (ALK+)	Phase III clinical trial	
10		FCN-437	Breast cancer 1L	Phase III clinical trial	Phase I clinical trial (in Hong Kong)
11			Breast cancer 2L	Phase III clinical trial	
12		01001	Adipogenic lipoma	Phase I clinical trial	
13		FH-2001	Adipogenic lipoma	Phase I clinical trial	
14	Malignant tumor	FCN-342	Glioma	Phase I clinical trial	
15	Hematology	IN1001	Immunohistochemical analysis (IF)	Phase I clinical trial	Phase I clinical trial (in Hong Kong)
16		E-26	Acute leukemia	Phase II clinical trial	
17		FCN-159	Advanced gastric cancer	Phase I clinical trial	

Table 6 — Biopharmaceutical innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese Mainland as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period	
1	Anti-tumor	Ha i h a (- e j l i a i j e i)	Mi t o c h o n d r i a l t a r g e t i n g (M I-H) l i n e	A n n o u n c e m e n t	A n n o u n c e m e n t l i n e (note 1)	
2		a - a l l e l a - e (N C L C)	A n n o u n c e m e n t	a - a l l e l a - e (i n t e r n a t i o n a l)		
3		Ha i h a (- e j l i a i j e i) + h e t e r o d i m e r	E p i d e m i o l o g i c a l a - e (E - C L C)	A n n o u n c e m e n t	a - a l l e l a - e (i n t e r n a t i o n a l)	
4			E p i d e m i o l o g i c a l a - e (E C C)	a - a l l e l a - e (note 2)		
5			N e u r o j e n e r a t o r G C	a - a l l e l a - e		
6		Ha i h a (- e j l i a i j e i) + h e t e r o d i m e r + h e t e r o d i m e r	L i n e t a r g e t a l l e l a - e (L - C L C)	a - a l l e l a - e (i n t e r n a t i o n a l)	a - a l l e l a - e (i n t e r n a t i o n a l)	
7			N - a - a l l e l a - e (N C L C)	a - a l l e l a - e		
8		Ha i h a (- e j l i a i j e i) + Ha B e i a i (- e j l i a i j e i)	H e t e r o d i m e r a r i a (HCC)	a - a l l e l a - e		
9			M e t a b o l i c a l a - e (C C)	a - a l l e l a - e		
10		Ha i h a (- e j l i a i j e i) + HLX07 (t e i a a i - E G F h e t e r o d i m e r)	a - a l l e l a - e (H N C C)	a - a l l e l a - e		
11			a - a l l e l a - e (N C L C)	a - a l l e l a - e		
12		Ha i h a (- e j l i a i j e i) + HLX07 (t e i a a i - E G F h e t e r o d i m e r) + Ha B e i a i (- e j l i a i j e i)	H e t e r o d i m e r a r i a (HCC)	A n n o u n c e m e n t		
13		HLX26 (t e i a a i - L A G - 3 h e t e r o d i m e r) + Ha i h a (- e j l i a i j e i)	L i n e t a r g e t a	A n n o u n c e m e n t		
14		HLX22 (a i h a a i - e j l i a i j e i - 2 (H E 2) h e t e r o d i m e r) + Ha B e i a i (- e j l i a i j e i)	G a n g l i o n e (GC)	a - a l l e l a - e		
15		HLX07 (t e i a a i - E G F h e t e r o d i m e r)	L i n e t a r g e t a l l e l a - e (h e t e r o d i m e r)	a - a l l e l a - e (note 3)	A n n o u n c e m e n t (i n t e r n a t i o n a l)	
16		HLX20 (t e i a a i - D - L 1 h e t e r o d i m e r)	L i n e	A n n o u n c e m e n t	a - a l l e l a - e (i n t e r n a t i o n a l)	
17		HLX26 (t e i a a i - L A G - 3 h e t e r o d i m e r)	L i n e t a r g e t a	a - a l l e l a - e		
18		HLX35 (t e i a h a i - E G F a i - 4 - 1 B B i n t e r n a t i o n a l)	L i n e	a - a l l e l a - e	a - a l l e l a - e (i n t e r n a t i o n a l)	
19		HLX301 (t e i a a i - D - L 1 a i - I G I i n t e r n a t i o n a l)	L i n e	A n n o u n c e m e n t	a - a l l e l a - e (i n t e r n a t i o n a l)	
20		HLX23 (t e i a a i - C D 7 3 h e t e r o d i m e r)	L i n e		A n n o u n c e m e n t (i n t e r n a t i o n a l)	
21		HLX53 (a i - I G I F i n t e r n a t i o n a l)	L i n e t a r g e t a	A n n o u n c e m e n t		
22		HLX60 (t e i a h a i - E G F a i - G A h e t e r o d i m e r) + Ha i h a (- e j l i a i j e i)	A n n o u n c e m e n t l i n e		(Note 4)	
23		BI	e i a H a E r h e t e r o d i m e r - H F F i	A n n o u n c e m e n t	a - a l l e l a - e	
24			HLX04 (t e i a a i - E G F h e t e r o d i m e r)	a - a l l e l a - e (A M D)	a - a l l e l a - e	a - a l l e l a - e (i n t e r n a t i o n a l)

Note 1: Ha i h a ( li a i j e , i) t e - d i v e , h e I N D a  v a l i , h e  i e , a - e , h e E s a , h e t , h e a t e i .

Note 2: I Ma 2022, ha-³ll i al² Ha i ha² (e-²ll i a i j e i) i² i ai² i h² h e² h e² i² h e² h e² i² all²
a² a² e² i² a² a² i² e² ha² a² a² e²ll a² i² a² e² h e² i² a² i² i² I A² 2022, h e² NDA i² Chi² e² Ma² i² a²
a² e² h e² NM A.

Note 3: A ^hhe ha-e I /l li i al t^hial t^he i Chi -e-e Mai la , t^hhe ha-e la li i al t^hial t^he i ai a t^he i , Chi a ha-ve -ee

Note 4: I A 2022, HLX60 (t e i a t h a i e a t i-GA l a l a t i i j e t i) i i a i i h Ha i h a (e h l i a i j e i) t h e t e a a a e / s a a i l i t a a a e t h a e l i i a l i a l A t a l i a .

Table 7 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	Anti-infective	N53-67/M57-KLH (anti-M)	Resistant influenza A	Advanced pre-clinical trial
2		HLX208	Anti-hepatitis B virus (HBV) infection, LCH and ECD	Phase II clinical trial
3		F-1502 (anti-hepatitis B virus)	HBV infection (NCLC)	Phase II clinical trial
4		HE-2 (anti-hepatitis B virus)	HBV infection	Phase I clinical trial
5		HE-2 (anti-hepatitis B virus)	HBV infection	Phase II clinical trial
6		F-1502 (anti-hepatitis B virus)	HBV infection	Advanced pre-clinical trial
7	Musculoskeletal	Anti-inflammatory	Inflammatory (IB-C)	Phase I clinical trial
8		Anti-inflammatory	Inflammatory	Phase III clinical trial
9	Anti-infective	NA anti-BN 162-2	Anti-hepatitis B virus (C-ID-19) (A-C-2) anti-hepatitis B virus	China Medical: Phase II clinical trial H-K, China: Anti-hepatitis B virus Ma'a, China: Anti-hepatitis B virus ai-a-he-i, China: Anti-hepatitis B virus ai-a-he-i, China: Anti-hepatitis B virus
10		Anti-inflammatory	Anti-inflammatory (XD) and (MD-B) anti-inflammatory	Phase I clinical trial
11	Cancer	Anti-cancer	Anti-cancer	NDA
12	Blood	Anti-cancer	Chronic (I)	Phase III clinical trial
13		Anti-cancer	Hepatic (E-D-HD)	Phase III clinical trial
14	Hematology	F-1502 (anti-hepatitis B virus)	Anti-hepatitis B virus	Phase III clinical trial
15		002 (Da-i-li-i-A)	M-anti-hepatitis B virus (GL)	Phase III clinical trial
16			Anti-hepatitis B virus (CD)	Phase III clinical trial

Table 8 — Biosimilars under independent development

[illegible]

Note 1: $\frac{h_c}{a} \cdot \frac{\rho_k}{\gamma_{af}} = \frac{f_{ct,d}}{NM A_i J I}$ 2022.

Note 2: h_c NDA H_a B.ei ai (\sqrt{a} in a i j e t i) t h_c e i i a i h_c t ell la r a r i a ha e e a e t h_c NM A i A t

[illegible][illegible]

Table 9 — Products won tenders for centralized procurement

[illegible]

he Gr i I e ha t he r i a i ve rai i ar i ve a ha r e a ar i
t e li e ea t e t e i ali , ra i , i i alia i a lja e ha t e i i
a a t ri e t t he Gr ha a e r alia i t e i i a a i a el 6,000 e l e e , a
a r a i e i a t i j i a e he a j r li e , ve ri t e ha 2,000 Cla III h i al ,
10,000 Cla I a Cla II h i al a a el 200,000 t ail har a t e I he a t t e ar , i r e t e e n a e i h
he la h i v i ve t a he t e i t e r ai alia i , he Gr t e he t a li h e t t he
i v i ve r e r alia i t e a t he t e ail t e a r Cla li e ha el , he e r alia i t e a r
A ri a E r a a h a a t r e a t e he i ve t e ve ri a ha e i a la ar ,
ar a e , t i al r a e i allia e a r a t i . I a i i , v j t e he t e r ai a li a e i h
i har , he Gr al t ll ilie i har , t e h i i t ri i t a l i i t a ilia e t e
e a i t a e ha el t he Gr har a e i al t t .

Medical Devices and Medical Diagnosis

h_e Gr^h e i al e j e i e ha i i j all t e t h t e e a j t i e i j i i h e i al e l ,
t e j r a t h e a l h a t e i al e i al a t e a h e t e .

I have identified a list of 10 items, with the first item being a Meiala tea set for \$175. The second item is a Meiala tea set for \$20.53. The third item is a Meiala tea set for \$175. The fourth item is a Meiala tea set for \$175. The fifth item is a Meiala tea set for \$175. The sixth item is a Meiala tea set for \$175. The seventh item is a Meiala tea set for \$175. The eighth item is a Meiala tea set for \$175. The ninth item is a Meiala tea set for \$175. The tenth item is a Meiala tea set for \$175.

[illegible]

a a r i h e a l h a a e e h e G r h e j e e h h e a a e f j e a e i i a l i e
 a a i l i e a h e e e e e h r h h e r a i i h e i a l i i t i , h a r a e , i r a e a i e
 a e e f j e , h e G r h e e l e a h e h e e f . l a i i , h e G r h a i l a e e i v e l i l l e t a r
 i h i e e e i a l i i t i , h e a l h e f j e e j e f , h a r a e a l i e l a r a e j e h e e f i h
 e t h e a l h a e e f j e a e e i a l - r a e r . A a h e e h e e i e f , h e h i e f j e
 v e e v e 40,000 a r e h a r a e . l e r a i i h G a h a r a a i h a r h e a l h l i e h e G r
 e a e i a i v e l i e e l i , a h e h e a l h a e e i i e i r a e e l a i i a l l a h e .

Pharmaceutical Distribution and Retail

D ri he ri , i har te te te ve te MB261,472 illi , MB6,229 illi a
 i a ri a le har h l er MB3,694 illi , 4.96%, 3.32% a 3.10%
 a ha i h he a ri la , ar, te i vel .

[illegible]

I tē tē i al ēj-e , i t hē ir t hal 2022, i har illi iline i ai al la i ē r ēj-e a a ili
a tē r-e all ai a v a-e ē i al ēj-e i t t t j-e all-ri i ri i ēj-e r v ri
vēr ē t a h ri ē a r ra-e t ēr hilē a a i t ē ē a a i ai . D ri t hē ē t i
ē ri , i har tē r-e a tēv-e MB53,684 illi r ē i al ēj-e i ē , tē tē ē i a ri -
ri r h 12.36%.

[illegible]

Financing

I t h e f e e e e i k e t h e e i a l t e , t h e G r h a e e i v e l t i m e t h e t i e i t h e i
h r h i v e r i l e i a i h a e l , a a i v e l t e i v a i a t a r a i , a t e k e h e l t e f
t a i a l e e v e l t e t .

[illegible]

I J I 2022, the C a the the li i a e A hate a e l i e 106,756,666 hate A
 hate, rai i MB4,484 illi . he a e a e i i a e e a e e ill e
 e r i a i e r li i al, li e e i a e e a e a e e r a i e
 har a e i al i e e a e e a i , a e l l a e e i h e e r i a i al. h e i a e ill a i l i a e h e
 Gr e e e & D e e r i l i a e e i a e a e e r i i e h e Gr i i a i a l
 e e e

2. Core Competitiveness Analysis

D r i t h e n d r i t h e k e n n i v e h e G r a d e l e t e i i - t l e & D . e l , r a r -
l i t e r a i a l l a r f e a i e r i a l i n i e a a h e a :

[illegible]

B. A *va* *a* *te* *i* *i* *fer* *ai* *al* *vel* *he* *Gr* *i* *le* *te* *i* *i* *fer* *ai* *al* *ai* *ra* *i* *li* *le*
i *te* *i* *i* *i* *i* *ai* *ve* &D, *li* *te* *te* *i* *le* *te* *i* *a* *ra* *i* *a* *te* *li* *ai* *li* *ai* *he*
Gr *ha* *li* *ve* *a* *al* *BD* *te* *te* *i* *i* *fer* *at* *a* *hr* *h* &D *ra* *i* *a* *li* *te* *te*
le *te* *he* *li* *al* *a* *te* *i* *ra* *te* *i* *he* *ve* *A* *ri* *a* *E* *te* *a* *li* *a* *i* *te* *te* *te*
ve *te* *te* *i* *ra* *a* *ai* *ai* *ai* *li* *le* *he* *Gr* *al* *a* *te* *ra* *te* *he* *i* *fer* *ai* *al* *al* *te*
te *i* *ai* *te* *i* *li* *te* *a* *te* *te* *i* *i* *fer* *ai* *al* *ar* *ai* *ai* *li* *te* *a* *te* *he*
te *he* *i* *fer* *ai* *al* *ar* *te*

[illegible]

3. Major Operations in the Reporting Period

A. Analysis on Principal Operations

(1) Analysis of Changes in Relevant Items of Financial Statements

Unit: million CNY; MB

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)
Revenue (Note 1)	21,275	16,878	26.05
Cost of sales (Notes 2, 7)	11,576	8,256	40.21
Profit from operations (Note 3)	4,166	4,211	1.07
Administrative expenses	1,715	1,505	13.95
R&D expenses	1,818	1,562	16.39
Financial expenses	438	421	4.04
Other income (Note 4)	651	1,645	60.43
Other expenses (Note 5)	911	338	169.53
Net profit attributable to shareholders	1,820	1,707	6.66
Net profit attributable to equity holders	2,485	2,450	1.43
Net profit attributable to ordinary shareholders (Note 6)	2,420	770	214.29

Note 1: For the same period, the company has completed the acquisition of the 100% equity of Ma'an Technology Co., Ltd. in the reporting period.

Note 2: The increase in cost of sales is mainly due to the increase in the cost of sales of the company's main products. The increase in the cost of sales is mainly due to the increase in the cost of sales of the company's main products. The increase in the cost of sales is mainly due to the increase in the cost of sales of the company's main products.

Note 3: Profit from operations decreased by 1.07% compared with the same period last year, mainly due to the increase in administrative expenses and R&D expenses. The increase in administrative expenses is mainly due to the increase in the cost of sales of the company's main products.

Di a Al

(2) *R&D expenditure*

① &D

 i: illi C rre : MB

&D.-e i t e-e -e i t h e ri	1,818
&D.-e i t e a i al i e i t h e ri	581
i al &D.-e i t e	2,399
i al &D.-e i t e a a i e t a e e v e e (%)	11.24
&D.-e i t e i h e har a e i al a a t ri e e t a a e t a e	
i h e e v e e i t h e har a e i al a a t ri e e t a a e t a e (%)	14.39
e t a e &D.-e i t e a i al i e (%)	24.22

② D. r. i.

[illegible]

B. Segment and Regional Operations

(1) *Principal Operations by Segments, Products and Regions*


 i: illi C rre : MB

By segments	Principal operations by segments					
	Revenue	Cost of sales	Gross profit	Period-on-	Period-on-	Period-on-
			margin (%)	period change in revenue (%)	period change in cost of sales (%)	period change in gross margin
hair care and accessories (Note 1)	14,271	6,509	54.39	17.18	24.84	2.80
Men's and women's grooming (Note 2)	4,035	2,650	34.32	42.48	74.69	12.11
Health and wellness (Note 3)	2,917	2,402	17.66	58.27	58.86	0.30

Principal operations by products


			Gross profit	Period-on-	Period-on-	Period-on-
By products	Revenue	Cost of sales	margin	period change	period change	period change
			(%)	in revenue	in cost of sales	in gross margin
				(%)	(%)	
Majlis al-Iqbal li-Ittifaqiyyah <i>(Note 4)</i>	2,550	493	80.67	49.56	27.06	3.43
Majlis al-Fikr li-Tadris al-Hukm <i>(Note 5)</i>	3,629	1,701	53.13	36.63	43.67	2.29
Majlis al-Fikr li-Tadris al-Hukm ali al-Mawla li-Ittifaqiyyah	1,383	289	79.10	2.54	-	0.53
Majlis al-Fikr li-Tadris al-Hukm <i>(Note 6)</i>	1,095	706	35.53	7.46	16.50	5.00
Majlis al-Fikr li-Tadris al-Hukm <i>(Note 7)</i>	422	41	90.28	31.49	6.82	2.58
Majlis al-Fikr li-Tadris al-Hukm A la Ittifaqiyyah	633	476	24.80	9.71	8.43	0.88

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin (%)
China (Note 8)	13,683	6,860	49.86	17.15	27.08	3.92
Other regions (Note 9)	7,592	4,716	37.88	46.06	65.01	7.14

Note 1:

Di a Al

Note 2: 
 he i lea i leye -e a ale he i al le i -e a le i al ia i -e -e a a le i h h e a -e ri
 la i -e a a i l -e : (1) h e r t h i ra M e i al i aj r ar -e t h a N r h A -e a E r (2)
 leye -e ri i r -e l la h e t h a C ID-19 a i -e -e i i a (3) n i i r -e a -e a i -
 -e i i t .

he - e t e a - i t t i ar i a t e h h e a - e ri la - e ar a ai l - e : (1) ha - e i t t t t e
 a a t e - e i t a - e Bi t h a t h e - e 2021; a (2) h e l - e t t i ar i t e a a l e -
 t t i ar a t i - e i t t i E l i h e - e - e i t a - e Bi t h a a l e - e t t i ar a t i -
 - e i t t h e t t ar i t h e - e i a l - e i a l a i - e - e t i t e a - e 0.2 t e t a - e i t
 t h e a - e a i .

Note 3:

h e i t e a e i t e v e e a t a l e r h e a l h a k e e f j e e e e t a p a k e i h t h e a e n i l a t e a t a a l i
e s h e r h l i e i e a h e e v e t e v e e r h t j a l .

[illegible]

Note 5:

Note 6:

he .e te.a.e.i t h i ar i he aj t h
ar l .e.t he i te.a.e.l he h i e aj t a a e r i al .e h t h e t
ar i all.

Note 7:

Note 8: 

[illegible]

Note 11: C₁ ale r₁ h₁ e a₁ e b₁ r₁ i 2021 ha₁ e e a₁ j₁ e h₁ e e a₁ i₁.

C. Subsidiaries and Investees

(1) Operation and Results of Major Subsidiaries of the Group

① Mainland China Major Subsidiaries

Unit: million CNY; MB

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
Da Hai	Real estate development and operation	197	7,053	5,037	2,542	474	410
Da Hai	Real estate development and operation	452	6,115	3,292	3,818	405	359
Glad	Real estate development and operation	N/A	8,976	7,725	1,667	481	360
Fujian (Note 1)	Investment and management	N/A	30,644	16,874	8,064	N/A	679

Note 1: The company is a wholly-owned subsidiary of the Group, established in Hainan, China, and is a real estate development and operation company.

Note 2: The company is a wholly-owned subsidiary of the Group, established in Hainan, China, and is a real estate development and operation company.

② Overseas Major Subsidiaries

Unit: million CNY; MB

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Net profit
Ha Hai (Note 1)	Real estate development and operation	543	8,184	2,078	1,289	252
Gili	Real estate development and operation	285	1,842	1,049	591	164
Fa Cha (Note 2)	Health care services	50	3,334	1,926	1,033	23
ira Mei (Note 3)	Medical services and operation	N/A	3,648	2,757	1,132	133

Note 1: The company is a wholly-owned subsidiary of the Group, established in Hainan, China, and is a real estate development and operation company.

Note 2: The company is a wholly-owned subsidiary of the Group, established in Hainan, China, and is a health care services company.

Note 3: The company is a wholly-owned subsidiary of the Group, established in Hainan, China, and is a medical services and operation company.

Management Discussion and Analysis

(2) Operation and Results of Investee Companies whose Net Profit and Investment Income Contributing More Than 10% of the Group's Net Profit

Unit: million RMB

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
Xi'an Hengsheng Pharmaceutical Co., Ltd.	Pharmaceuticals	100	370,124	104,237	261,472	7,988	6,221

(3) Acquisition and Disposal of Subsidiaries for the Reporting Period (including the Purposes and Methods of the Acquisitions and Disposals and their Effects on the Group's Overall Operation and Results)

- ① Acquisition of subsidiaries: During the reporting period, the Group acquired Xi'an Hengsheng Pharmaceutical Co., Ltd. through equity purchase. The acquisition was completed on January 20, 2022. The acquisition price was 646 million RMB. The net assets of the acquired subsidiary at the end of the reporting period were 104,237 million RMB, and the net profit was 6,221 million RMB.

Unit: million RMB

Company name	Acquired through	Net assets (as at the end of Reporting Period)	Net profit (from date of merger/ acquisition up to the end of Reporting Period)	Date of acquisition/ merger
Xi'an Hengsheng Pharmaceutical Co., Ltd.	Equity purchase	646	8	20 January 2022

Note: The acquisition of Xi'an Hengsheng Pharmaceutical Co., Ltd. is a business combination under common control.

- ② Disposal of subsidiaries: During the reporting period, the Group disposed of Xi'an Hengsheng Pharmaceutical Co., Ltd. through equity transfer. The disposal was completed on January 20, 2022. The disposal price was 646 million RMB. The net assets of the disposed subsidiary at the end of the reporting period were 104,237 million RMB, and the net profit was 6,221 million RMB.

Unit: million RMB

Company name	Disposed through	Net assets as at date of disposal	Net profit from beginning of Reporting Period to date of disposal	Date of disposal
Hengsheng Pharmaceutical Co., Ltd.	Equity transfer	30		3 January 2022
Xinsheng Pharmaceutical Co., Ltd.	Debt restructuring			21 February 2022
Hengsheng Pharmaceutical Co., Ltd.	Equity transfer	58	5	28 February 2022

D. Employees and Remuneration Policies

A a t h e e t h e e n i e r i t h e G r h a a t t a l 36,604 e n e e h e e n e e' k e e r a i
n l i e t h e G r a t e r l a t h e a i t h e e r a e r e r i e e a a l a r l e v e l l e v a i l i
t h e a r g

E. Assets and Liabilities Analysis

[illegible]

A a t h e e h e t i i r i t h e G r t e a t a t i MB169 illi , a a t e i h MB1,115 illi a a t 31 D e e t 2021. h e r i - t r i e k a t e i t t e t a a a i l e t a e k a e i t t e a a e e l i e r i e h a t e i B N X h e l t h e G r t a t h e e t h e t i r i a a t e i h h e e 2021.

4. Outlook for Operations in the Second Half of 2022

I t h e h a l 2022, t h e G r i l l i t h e h e i l i e v a r i i j i a
t h e a v a i l i t e r a i a l l i t h e G r i l l e a v t i n e i t t e a i v e
& D i l e , i t i n e r a l a l e i l e i t h e h a l h a k e t e j i e i t t h e a t t h e i
i i v e i i l i e a t h a e a l i a a e e t e t h e h e i t e t t a r a i h a l h a t e i t t a
t h e t t h e h i t h e t e l t e l a t e t h e t r a i a t a i t v e i
a a i l i e i t r a i a a e t a i t e r a i a l l i i . I a i i , t h e G r i l l i t t a a t t e i
t e t a a i i t i e e l l e t e t e t t e a r a a a h e . A t h e a t e i t t h e G r i l l
i t e t e t t e t a t e t e r a l i a i t h a t i n e i t i a i a l t t t e a i t e t t t e
l e a t r a i t e t a i t v e e i l e . I a i i , t h e G r i l l i t t a a t t e i t t h e
i a i C I D - 19 a a t t e l e v t t e v e i v e e a t e t e t h e t e t t h a t a t t e a
t r a i a i l l e .

I r-er-t a hi-ve he a ve-rai je-t-ve, he Gr ill a-ti-e-ti-je-ti-t l hr h t-rai
a-e ha-e he-e i-je a-rai-i-je-t-ve a-ti-e-ti-je-ti-t l hr h t-rai

Pharmaceutical Manufacturing

[illegible]

Medical Devices and Medical Diagnosis

I the hal 2022, i the te i al e i e , the Gr ill i e i al
i ve rai a e rai a i e e ra &D a e e e a hr h. hr h i v r i e e a
i l i i i e a e i &D e i e l i e e i a e rai , the e i a l a l a r e v e l e t
he e i al e i e i e ill e t h e r i h e e i al e l , the Gr ill i e i al
e ha e he &D i v r i e e t t t l i , a e l e r a e h e i v e t e t a h e i e rai e a r i h e
i i a l i a i , e e e i v e t e t a e e l e t i i t e a l e h a e l a e e e i a l , a a i v e l e t e t
e t e l l a rai v e e l rai a i e e l i a i . i h e e t t t e r a r h a l h , the Gr ill e a
h e h l t l i , e e l a h i e e t a e h e i v e t i t l i e a e , r i e l e
a e e r a t a e a e l e r a e h e l a h t i e e a e i t h e e e h e C h i e e a r e , a
i i e e e i e t e t e h r h i i a l e a . i h e t t t e i a l h a l h a e , the Gr ill i e
i l e a e &D e e i e a a i v e t i l i a l l i i h e e i a l e t h r h i - h e &D a
l i e e i e t a e e l h i h - a l i &D a e i a a i t h r h i t r i a l h a e e i . the Gr ill
a l a i v e l e t h e i e a e i a l l a i v l e a r i a l v l e a e l l a h e l i a l a a e i e v e l e t
Da i i r i a l t i e .

[illegible][illegible]

Healthcare Services

I he e hal 2022, Leve ra i he a va a e e i i i al ja r a e i al te r e, he Gr ill
 i e a e l e r a e h e i e l a i h e l e i i al e i al e j e, i al i n e i al e j e a h e a l h
 a a e e e j e, a i l i a i h e i e r a i l i e a l i e e j e a i l i a l i n e a a i l i e
 a a l l i l e l e a a e e t i e a e a i e t i e a e e . h i e, he Gr ill i e t a l
 t e h e e a a i - i l i, i l i h e l i a i h e e r r e r e, h e r i h e t i a l
 t a e j e, h e h a e e r i j a i l i e t i i a e h l i a l i a i, h e e e e i t h e
 e e e e i r a e a h e i i e e i h e a l l i t r l a a l i a e e e .

Management

Directorial Affairs

The Board of Directors of the Company is composed of 11 members, including 3 independent non-executive directors and 8 executive directors. The Board is responsible for the overall management of the Company and the implementation of the business strategy. The Board also oversees the management of the Company's financial and operational performance. The Board is composed of members with diverse backgrounds and expertise, ensuring a comprehensive and balanced approach to the Company's management. The Board's responsibilities include setting the Company's strategic direction, approving the annual budget, and monitoring the Company's performance against its goals. The Board also oversees the Company's risk management and compliance with applicable laws and regulations. The Board is committed to ensuring the Company's long-term success and the interests of its shareholders.

The Board of Directors of the Company is composed of 11 members, including 3 independent non-executive directors and 8 executive directors. The Board is responsible for the overall management of the Company and the implementation of the business strategy. The Board also oversees the management of the Company's financial and operational performance. The Board is composed of members with diverse backgrounds and expertise, ensuring a comprehensive and balanced approach to the Company's management. The Board's responsibilities include setting the Company's strategic direction, approving the annual budget, and monitoring the Company's performance against its goals. The Board also oversees the Company's risk management and compliance with applicable laws and regulations. The Board is committed to ensuring the Company's long-term success and the interests of its shareholders.

The Board of Directors of the Company is composed of 11 members, including 3 independent non-executive directors and 8 executive directors. The Board is responsible for the overall management of the Company and the implementation of the business strategy. The Board also oversees the management of the Company's financial and operational performance. The Board is composed of members with diverse backgrounds and expertise, ensuring a comprehensive and balanced approach to the Company's management. The Board's responsibilities include setting the Company's strategic direction, approving the annual budget, and monitoring the Company's performance against its goals. The Board also oversees the Company's risk management and compliance with applicable laws and regulations. The Board is committed to ensuring the Company's long-term success and the interests of its shareholders.

The Board of Directors of the Company is composed of 11 members, including 3 independent non-executive directors and 8 executive directors. The Board is responsible for the overall management of the Company and the implementation of the business strategy. The Board also oversees the management of the Company's financial and operational performance. The Board is composed of members with diverse backgrounds and expertise, ensuring a comprehensive and balanced approach to the Company's management. The Board's responsibilities include setting the Company's strategic direction, approving the annual budget, and monitoring the Company's performance against its goals. The Board also oversees the Company's risk management and compliance with applicable laws and regulations. The Board is committed to ensuring the Company's long-term success and the interests of its shareholders.

B. Market risks

With the continuous improvement of the company's management system, the company's management system is becoming more and more mature. The company's management system is becoming more and more mature. The company's management system is becoming more and more mature.

In the past, the company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature.

In the past, the company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature.

In the past, the company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature.

C. Business and operating risks

(1) R&D risk of drugs

Drugs are the company's main business. The company's main business is drugs. The company's main business is drugs. The company's main business is drugs. The company's main business is drugs.

In the past, the company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature. The company's management system was not very mature.

(2) Control risk of product/service quality

hār a-e-i al n̄, -e-i al -e-j-e a -ia i n̄ ake n̄ i al i le, a he i le
n̄ a -e-i al a-e-i hār ali. he Gr n̄ ha -e-i i i le i a a-e-e
-e-i a i ve-e-i h i al ra r ai i -e-i ali a a-e-e. he h i a
-e-i n̄ a ar -e-i h i i ar ha ve -e-i i i a i i n̄ ve. H -e-ve, -e-i he a
n̄ i a -e-i r hār a-e-i al n̄, ali i -e-i a a-e-e -e-i ra a-e-i al, n̄ i,
ra n̄ ai, i ra -e-i ve i, -e-i hār a-e-i. Mea hile he Gr n̄ ha al a a he-e-i
n̄ i i le n̄ ai i n̄ i a -e-i h la a -e-i la i, a he Gr n̄ ha r la-e-i n̄ i
a a-e-e -e-i a -e-i a li he a a-e-e -e-i a -e-i -e-i he ha he n̄ -e-i, i ve i,
n̄ ai, a -e-i hār a-e-i al, -e-i al -e-j-e, a -ia i n̄ n̄ i h GM a
le-e-i -e-i a all i i a n̄ ai a r a -e-i h h la. H -e-ve, he a ill -e-i
n̄ i i le ha he le-e-i n̄ ai -e-i i le ill -e-i n̄ i he r ali i i le-e-i a i al
la a -e-i la i -e-i n̄ i le ha n̄ a a-e-e -e-i he a al -e-i n̄ ai.

he hē al h ake -e-j-e -e-i a -e-i -e-i i -e-i al al a i -e-i la i r i n̄ i, i i
n̄ ai a i n̄ i -e-i -e-i r a n̄ i a i r i al -e-i r, -e-i al i a i a
i i -e-i le-e-i -e-i -e-i a -e-i i -e-j-e. I he -e-i -e-i -e-i al al a i -e-i
le-e-i n̄ ai a i a -e-i n̄ i he Gr n̄ hi h a i r a -e-i he n̄ ai le i,
ra a ar -e-i n̄ ai he Gr n̄ hē al h ake -e-j-e -e-i.

I hi le ar, he Gr n̄ ill i -e-i ali a ri a a-e-e -e-i h h hē i -e-i i
n̄ i, a i n̄ i -e-i ali a a -e-i r i -e-i ha i a hār a j lā -e-i ha i.
Mea hile, a i lea n̄ ai a a -e-i, a he a i -e-i n̄ i -e-i al -e-j-e -e-i he
Gr n̄ ill he i i i i a i n̄ j he ali n̄ ai.

(3) Safety and environmental risks

Ma a i n̄ i a e ake al -e-i -e-i a a -e-i j r -e-i al ri ri he n̄ i i n̄ i -e-i
he n̄ i -e-i i r, -e-i al -e-j-e a -ia i n̄ i, -e-i a -e-i he a -e-i
he i al a -e-i v i he i r, i n̄ i n̄ ai ri a -e-i a i -e-i a -e-i ri
la i, i la i, ha li, i ra -e-i a a -e-i i a -e-i -e-i a -e-i a, a -e-i
li i a he r ll a i n̄ i -e-i ri he n̄ i i r n̄ j i hē al h ake -e-j-e ill -e-i
hār i i he -e-i j r -e-i i he ake -e-i n̄ i n̄ i, hi h i r ill a -e-i he r al
n̄ i a n̄ ai he Gr n̄ De -e-i he ri n̄ i a -e-i he Gr n̄ he le-e-i
-e-i j r -e-i al n̄ i la, le la i a a ar i a -e-i a -e-i i i le-i
a -e-i a a -e-i i -e-i j r -e-i al a ar, he -e-i j r -e-i al n̄ i i i n̄ i
he Gr n̄ a i -e-i li h -e-i ha -e-i i al a ake -e-i j r -e-i al n̄ i i
he n̄ i i a i -e-i i -e-i j r -e-i al n̄ i la a -e-i la i -e-i r al
i al -e-i.

I hi le ar, he Gr n̄ he he n̄ i a -e-i a a -e-i -e-i a r ai i, i n̄ i -e-i
le-e-i a n̄ i -e-i a -e-i a i r i. Mea hile he C n̄ ill i i
a a h i n̄ i -e-i i i i i al le n̄ i i i r -e-i j r -e-i al n̄ i i, a he-e-i he n̄ i i le ha
-e-i -e-i n̄ i a -e-i al a i a le -e-i n̄ i i le -e-i i -e-i j r -e-i al
n̄ i i a -e-i he r al n̄ ai -e-i j r -e-i al n̄ i a i i le a ha he ar -e-i
-e-i i i -e-i.

D. Management risks

(1) Risks of internationalization

The Group has a long history of internationalization, and has established a global network of sales and distribution channels. However, internationalization also brings risks. First, the Group's international operations are subject to various political, economic, and legal risks. Second, the Group's international operations are subject to various currency exchange risks. Third, the Group's international operations are subject to various cultural and language risks. Fourth, the Group's international operations are subject to various talent risks. Fifth, the Group's international operations are subject to various information technology risks. Sixth, the Group's international operations are subject to various environmental risks. Seventh, the Group's international operations are subject to various social risks. Eighth, the Group's international operations are subject to various ethical risks. Ninth, the Group's international operations are subject to various reputational risks. Tenth, the Group's international operations are subject to various other risks.

(2) Risks arising from mergers, acquisitions and restructuring

The Group has a long history of mergers, acquisitions and restructuring, and has established a global network of sales and distribution channels. However, mergers, acquisitions and restructuring also bring risks. First, the Group's mergers, acquisitions and restructuring are subject to various political, economic, and legal risks. Second, the Group's mergers, acquisitions and restructuring are subject to various currency exchange risks. Third, the Group's mergers, acquisitions and restructuring are subject to various cultural and language risks. Fourth, the Group's mergers, acquisitions and restructuring are subject to various talent risks. Fifth, the Group's mergers, acquisitions and restructuring are subject to various information technology risks. Sixth, the Group's mergers, acquisitions and restructuring are subject to various environmental risks. Seventh, the Group's mergers, acquisitions and restructuring are subject to various social risks. Eighth, the Group's mergers, acquisitions and restructuring are subject to various ethical risks. Ninth, the Group's mergers, acquisitions and restructuring are subject to various reputational risks. Tenth, the Group's mergers, acquisitions and restructuring are subject to various other risks.

E. Foreign exchange risk

The Group has a long history of foreign exchange risk, and has established a global network of sales and distribution channels. However, foreign exchange risk also brings risks. First, the Group's foreign exchange risk is subject to various political, economic, and legal risks. Second, the Group's foreign exchange risk is subject to various currency exchange risks. Third, the Group's foreign exchange risk is subject to various cultural and language risks. Fourth, the Group's foreign exchange risk is subject to various talent risks. Fifth, the Group's foreign exchange risk is subject to various information technology risks. Sixth, the Group's foreign exchange risk is subject to various environmental risks. Seventh, the Group's foreign exchange risk is subject to various social risks. Eighth, the Group's foreign exchange risk is subject to various ethical risks. Ninth, the Group's foreign exchange risk is subject to various reputational risks. Tenth, the Group's foreign exchange risk is subject to various other risks.

F. Force majeure risks

The Group has a long history of force majeure risks, and has established a global network of sales and distribution channels. However, force majeure risks also bring risks. First, the Group's force majeure risks are subject to various political, economic, and legal risks. Second, the Group's force majeure risks are subject to various currency exchange risks. Third, the Group's force majeure risks are subject to various cultural and language risks. Fourth, the Group's force majeure risks are subject to various talent risks. Fifth, the Group's force majeure risks are subject to various information technology risks. Sixth, the Group's force majeure risks are subject to various environmental risks. Seventh, the Group's force majeure risks are subject to various social risks. Eighth, the Group's force majeure risks are subject to various ethical risks. Ninth, the Group's force majeure risks are subject to various reputational risks. Tenth, the Group's force majeure risks are subject to various other risks.

6. Other Events

A. Non-public issuance of A Shares

On July 1, 2021, the Company issued 128,144,927 A Shares at a price of RMB42.00 per share, totaling RMB5,390,086,928.00. The Company has received the approval of the Shanghai Stock Exchange and the China Securities Regulatory Commission for the non-public issuance of A Shares.

On July 1, 2022, the Company issued 106,756,666 A Shares at a price of RMB42.00 per share, totaling RMB4,483,779,972.00. The Company has received the approval of the Shanghai Stock Exchange and the China Securities Regulatory Commission for the non-public issuance of A Shares.

On July 1, 2022, the Company issued 106,756,666 A Shares at a price of RMB42.00 per share, totaling RMB4,483,779,972.00. The Company has received the approval of the Shanghai Stock Exchange and the China Securities Regulatory Commission for the non-public issuance of A Shares.

B. Inter-bank Market Debt Financing Instruments

1. March 2022, the Company has received the interest on the loan of 3.50% at the end of 2022. The amount of the interest is MB0.5 million and the amount of the interest is 2+2 years.

In April 2022, the C₁₈ and C₁₉ homologs in the MB0.6 elli were detected at 2.65% and 120% of the expected abundance.

C. The Public Issuance of Corporate Bonds to Qualified Investors

I.F.E.R ar 2022, a r i h e l e l i a h e 2022 ir h l e t' e g i h e n o l i i a e h e
e ra h e r r a e t t h e l e l i a h e 2022 ir h l e t' e g i h e n o l i i a e h e
(2) ha hai F har a e i al (Gr) C , L * i 2018 (18 F
har a 03) (上海復星醫藥(集團)股份有限公司2018年公開發行公司債券(第二期)(品種二)(18復藥03), h r r a e
e e l i e a h e C a h e h e a e h e l e a i i r i i a l MB8.95 illi h
r r a e a l h e i i t e t r i h e r i r 30 N v e e r 2021 t 15 E r ar 2022
(h a e i l i y).

On March 22, 2022, the applicant filed MB1,091.95 with the U.S. Patent and Trademark Office (USPTO) for the invention of a method for treating a patient with a disease or condition. The applicant claims that the invention is a novel and non-obvious improvement over the prior art. The applicant also claims that the invention is a significant advance in the field of medicine. The applicant has provided evidence to support these claims, including a detailed description of the invention and a comparison of the invention to the prior art. The USPTO has granted the applicant a patent for the invention, and the applicant has filed a lawsuit to enforce the patent. The lawsuit is currently pending in the U.S. District Court for the District of Columbia.

RESULTS AND DIVIDENDS

The Group has not declared any dividends for the year ended 30 June 2022 and the directors do not recommend the payment of dividends for the year ended 30 June 2022.

The Board has not declared any dividends for the year ended 30 June 2022.

PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

Neither the Company nor any of its subsidiaries has purchased, sold or redeemed any of the Company's listed securities during the year.

DIRECTORS

A total of 10 directors are appointed to the Board, of whom 3 are independent non-executive directors and 7 are executive directors.

Executive Directors

Mr. Wu Yifang (吳以芳) (Chairman)
Mr. Wang Kexin (王可心) (Co-Chairman)
Mr. Guan Xiaohui (關曉暉) (Vice-Chairman)

Non-executive Directors

Mr. Chen Qiyu (陳啟宇)
Mr. Yao Fang (姚方)
Mr. Xu Xiaoliang (徐曉亮)
Mr. Pan Donghui (潘東輝)

Independent Non-executive Directors

Ms. Li Li (李玲)
Mr. Tang Yuliang (湯谷良)
Mr. Wang Qian (王全弟)
Mr. Yu Zishan (余梓山)

A general meeting of the shareholders of the Company was held on 1 July 2022, at which the shareholders elected Mr. Wu Yifang, Mr. Wang Kexin and Mr. Guan Xiaohui as executive directors and Mr. Chen Qiyu, Mr. Yao Fang, Mr. Xu Xiaoliang and Mr. Pan Donghui as non-executive directors. The shareholders also elected Ms. Li Li, Mr. Tang Yuliang, Mr. Wang Qian and Mr. Yu Zishan as independent non-executive directors. On 1 July 2022, Mr. Wu Yifang was elected as Chairman, Mr. Wang Kexin as Co-Chairman and Mr. Guan Xiaohui as Vice-Chairman of the Board.

At the 2022 ordinary shareholders' meeting held on 10 April 2022, the following persons were elected as the first three directors: Mr. Chen, Mr. Li and Mr. Wang. The following persons were elected as the first three supervisors: Mr. Chen, Mr. Li and Mr. Wang.

SUPERVISORS

At the 2022 ordinary shareholders' meeting held on 10 April 2022, the following persons were elected as the first three supervisors: Mr. Chen, Mr. Li and Mr. Wang.

Mr. Chen (任倩) (Chairman)

Mr. Cao (曹根興)

Mr. Guan (管一民)

At the 2022 ordinary shareholders' meeting held on 10 April 2022, the following persons were elected as the first three supervisors: Mr. Chen, Mr. Li and Mr. Wang. The following persons were elected as the first three supervisors: Mr. Chen, Mr. Li and Mr. Wang.

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

Mr. Chen, a director, has resigned from his position as a director of the Company. He has been replaced by Mr. Li. The resignation of Mr. Chen took effect from 10 April 2022.

Mr. Guan, a supervisor, has resigned from his position as a supervisor of the Company. He has been replaced by Mr. Li. The resignation of Mr. Guan took effect from 15 April 2022.

Mr. Guan, a supervisor, has resigned from his position as a supervisor of the Company. He has been replaced by Mr. Li. The resignation of Mr. Guan took effect from 16 April 2022.

At the 2022 ordinary shareholders' meeting held on 10 April 2022, the following persons were elected as the first three supervisors: Mr. Chen, Mr. Li and Mr. Wang.

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

hač'h l-er t_{he}C a a ve , a t_{her}, t_{he} Gla har a hač'e i l-er i ve he-re 25 J-re 2019. he
t_r-re t_{he} Gla har a hač'e i l-er i ve he-re i t_(i) ke ar t_{he}-re t_{he}-re t_{he}it a t_{ke}
t_r a -re (ii) ali t_{he}i t_{ke}t_{he} t_{he}-re t_{he}-re i h h-re hač'h l-er t_{Gla} har a, (iii) t_{er}t_{he}-re
-er hi t_{he}-re t_{he}-re a (iv) ke ar t_{he}-re t_{he}-re t_{he}it l al .

Mar h 2020, t he a i t he Gla har a hake i l e i ve he e a t e r Gla har a' hake i j i 17
 r a i i a t e r h e Gla har a hake i l e i ve he e hall t e e 1,704,440 Gla har a hake,
 t e e t i a n i a l 1% h e t a l e r i e Gla har a hake a a h e a e h i t e n t . j e t t h e
 l i i a i n e r i e t h e Gla har a hake i l e i ve he e Gla har a t e r v e h e r i h t i t e a e r
 t e e h e r Gla t har a hake a i e e .

[illegible]

17 Mär h 2020, Gla har a he he ha ke i ji he ai ha -ver -e (1) a i Gla har a
ha ke -e i ji -e i t -e (10) Gla har a ha ke . A r i he ai ji he Gla har a ha ke i I -e i ve
he -e he he i he ha ke i ji Gla har a, a j -e hall -e a -e i he -e i -e ri -e he
t t a i i a he -e r Gla har a ha ke t -e all -e a i -e -e -e i -e all he t t a i
i i a r a -e i h he -e r he Gla har a ha ke i I -e i ve he -e

h_e -t ail t_h ha -e i t_h t a i i -t h_e Gla har a ha_k_e i l -e t ve h_e -e ri t_h

Participant	Date of Grant (dd-mm-yyyy)	Vesting Period (dd-mm-yyyy) ⁽¹⁾	Option share ⁽¹⁾	Exercise period (dd-mm-yyyy) ⁽¹⁾	Outstanding options as at 1 January 2022	Exercise price per share	Granted	Exercised during the Reporting Period ⁽²⁾	Forfeited or lapsed during the Reporting Period	Outstanding options as at 30 June 2022
							during the Reporting Period			
E. N. Glaser	27.6.2019	19.11.2020	40%	20.11.2020 - 26.6.2029						
Chairman	27.6.2019	30.3.2021	30%	31.3.2021 - 26.6.2029	455,500	IN 542	0	353,200	0	102,300
	27.6.2019	30.3.2022	30%	31.3.2022 - 26.6.2029						

Notes:

- [illegible]

Fosun Health Share Option Scheme

he hahē l-er a-er ve, a t-he' hi t-he F Healh hake i he e-a t-he a al e-er al e-er i hē
 1J e-2022. he h-er e t-he F Healh hake i he e-i t-e i-vel a-ra t-a e-ai e-ale t i h i i a t
 i l-e e a ri t i t he F Healh Gr i e t h, e a li t-a e ha l e-i e t ali i e-er
 e-er i hahē l-er a t a-er r, i t-a-e e-er a i t e-er e-er h i a e-er t he F Healh
 Gr l t-er e-er e-er.

he t al ha ke a i al ha tte he a te a e er i ha ke i te he t he i te ra te er
he F Heal h ha ke i he e hall te ee MB380,435,000 he te i te a i al F Heal h, r hall i
te ee 10% he al te i te a i al F Heal h a a he a e hi h he F Heal h ha ke i he e a
a ve a t he ha ch l er i F Heal h. he er i e ri e r he i a ral i ra t er he F
Heal h ha ke i he e ill te MB1.0 er i ha ke F r ra () a er he i a ral i ra t he er i e ri e
i ra te ill te he hi h er 50% he air val er ha ke (ie er MB1 te i te a i al) F Heal h (i a) a
t he i te he t he i ra t i a ve t he ar te r F Heal h a t he a a val er ha ke (ie er
MB1 te i te a i al) F Heal h a t he i te he i ra t a he er i e ri e hall te le ha t he
er i e ri e i ra te i he l a t ral i ra t he F Heal h ha ke i he e hall te er i e ri e
er i 10 er r he a e t hi h he F Heal h ha ke i he e a a te he ha ch l er i
F Heal h.

D ri he e ri ri , i F H e a l h e e r a e e e h e F H e a l h h a e i h e e

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

A 30 J 2022, he i t e t r h t i i he Di t r, r j r a he t e t i v e C a i t he h a f e, f l i h a f e a t e t t e C t r a t i a i a e r a i (i h i t e t a i a r X t F) h i h h l t e r e i t e t i t e i t e t e C t r a t t t e t i 352 t e F, r a t h e r i e h l t e t i t e C a a h e H K t E h a t r a t t t e M t C t a t t i A i 10 t h e H K L i t e t e a t l l :

(1) Long positions in the Shares, underlying Shares and debentures of the Company

Name of Directors/ chief executive	Capacity	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

A 30 J 2022, at a i the Dite r a r j r, the r r i i e, the ha the Dite t r
C hi h l all t e i l e the C r h t i i he hake r e l i hake t he
h e e e e i t e l r i i t e l i t e t e i 5% r t e he i al val e a la hake a l a l a r t i
ri h t v e i all t r a e a e e r a l e q i the C e e a l l :

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
F. Hoffmann-La Roche Ltd.	Beneficial owner	Ordinary Shares	71,533,500 (L)	12.96%
F. Hoffmann-La Roche Ltd.	Beneficial owner	Preferred Shares	938,095,290 (L)	46.65%
F. Hoffmann-La Roche Ltd.	Beneficial owner	Ordinary Shares	6,000,000 (L)	1.09%
F. Hoffmann-La Roche Ltd.	Beneficial owner	Ordinary Shares	71,533,500 (L) ⁽²⁾	12.96%
F. Hoffmann-La Roche Ltd.	Beneficial owner	Preferred Shares	938,095,290 (L) ⁽⁴⁾	46.65%
F. Hoffmann-La Roche Ltd.	Beneficial owner	Ordinary Shares	77,533,500 (L) ⁽³⁾	14.05%
F. Hoffmann-La Roche Ltd.	Beneficial owner	Preferred Shares	938,095,290 (L) ⁽⁴⁾	46.65%
F. Hoffmann-La Roche Ltd.	Beneficial owner	Ordinary Shares	77,533,500 (L) ⁽³⁾	14.05%
F. Hoffmann-La Roche Ltd.	Beneficial owner	Preferred Shares	938,095,290 (L) ⁽⁴⁾	46.65%
Mr. George A. Haefliger	Beneficial owner	Ordinary Shares	77,533,500 (L) ⁽³⁾	14.05%
Mr. George A. Haefliger	Beneficial owner	Preferred Shares	938,095,290 (L) ⁽⁴⁾	46.65%
BlackRock, Inc.	Beneficial owner	Ordinary Shares	114,075 (L)	0.01%
BlackRock, Inc.	Beneficial owner	Ordinary Shares	29,489,216 (L)	5.34%
			401,000 ()	0.07%

Notes:

- (1) (L) L h ; () h h
- (2) h h h F Hi h h. F Hi h h i h ll F I a i a a h h F I a i a l i e e e e
- i e e i h h h .
- (3) h h h , hi h 71,533,500 h h , a h F Hi h h a , hi h 6,000,000 h h , a h F I a i a l. F Hi h h i h ll F I a i a l, hi h i i e a 72.45% F H l i , a F H l i i a h ll - e i i F I a i a l H l i . F I a i a l H l i i e a 85.29% Mr. G G a h . h h h , F H l i , F I a i a l H l i a Mr. G G a h a e e e e i e i e e i h h h .
- (4) h h h h F Hi h h. F Hi h h i h ll F I a i a l, hi h i i e a 72.45% F H l i , a F H l i i a h ll - e i i F I a i a l H l i . F I a i a l H l i i e a 85.29% Mr. G G a h . h h h , F I a i a l, F H l i , F I a i a l H l i a Mr. G G a h a e e e e i e i e e i h h h .

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

According to the relevant provisions of the Company Law of the PRC, the Directors and Supervisors of the Company shall have the right to acquire shares or debentures of the Company. The Company shall not have the right to acquire shares or debentures of the Company.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Company has adopted the Model Code for Securities Transactions of the Company, which is applicable to the Directors and Supervisors of the Company.

However, the Company has not yet adopted the Model Code for Securities Transactions of the Company, which is applicable to the Directors and Supervisors of the Company.

COMPLIANCE WITH THE CG CODE

According to the relevant provisions of the Company Law of the PRC, the Directors and Supervisors of the Company shall have the right to acquire shares or debentures of the Company. The Company shall not have the right to acquire shares or debentures of the Company.

The Company has adopted the Model Code for Securities Transactions of the Company, which is applicable to the Directors and Supervisors of the Company.

According to the relevant provisions of the Company Law of the PRC, the Directors and Supervisors of the Company shall have the right to acquire shares or debentures of the Company. The Company shall not have the right to acquire shares or debentures of the Company.

According to the relevant provisions of the Company Law of the PRC, the Directors and Supervisors of the Company shall have the right to acquire shares or debentures of the Company. The Company shall not have the right to acquire shares or debentures of the Company.

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

A a hē hē rī rī , hē a i i hē C a rī t hē i t tē i vē

Ditē , a Mī a G liā (hāi a), Mī a i a M . Li Li .

h_e ai t_e h_e a i i_{ee} h_e C a at_e t_e v_e a i t_e h_e i a ial t_e i t_e t_e , ri
a a t_e t_e a i t_e al t_e h_e C a , a t_e v_e t_e t_e a i a a j t_e h_e B at_e .

h₂a i₂ i₂ h₂C a ha i₂ i₂ h₂ a i₂ i₂ i₂ i₂ h₂ i₂ i₂ i₂ i₂ h₂Gr i₂ i₂ h₂ i₂

Wu Yifang
Chairman

ha hai, h_e C
29 A ↑ t₂₀₂₂

Interim Condensed Consolidated

Financial statements for the six months ended 30 June 2022

		For the six months ended 30 June	
		2022 RMB'000 (Unaudited)	2021 MB'000 (Unaudited)
	Notes		
REVENUE	5	21,274,606	16,877,537
Cost of sales		(11,575,661)	(8,256,422)
Gross profit		9,698,945	8,621,115
Other income	6	183,645	141,714
Administrative expenses		(4,166,397)	(4,211,431)
Amortisation of intangible assets		(1,715,275)	(1,505,057)
Research and development expenses		(1,818,335)	(1,561,885)
Impairment loss on financial assets		(22,860)	(14,804)
Impairment loss on other non-current assets	7	651,104	1,645,255
Impairment loss on equity investments		(911,494)	(338,367)
Impairment loss on other non-current assets		118,416	116,605
Financial expenses	8	(438,187)	(420,725)
Share of profit/loss of associates		(99,564)	(93,817)
Joint venture		898,583	925,626
PROFIT BEFORE TAX	9	2,378,581	3,304,229
Income tax expense	10	(509,086)	(550,647)
PROFIT FOR THE PERIOD		1,869,495	2,753,582
Attributable to:			
Ordinary equity holders		1,553,504	2,482,373
Non-controlling interests		315,991	271,209
		1,869,495	2,753,582
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
Basic		RMB0.60 Yuan	MB0.97 Yuan
Diluted		RMB0.60 Yuan	MB0.97 Yuan

Interim Condensed Consolidated

For the six months ended 30 June 2022

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Unaudited)
PROFIT FOR THE PERIOD	1,869,495	2,753,582
OTHER COMPREHENSIVE INCOME		
Exchange differences in translating foreign currency financial statements	115,920	(201,712)
Share of other comprehensive income of associates and joint ventures	48	(804)
Share of other comprehensive income of subsidiaries	(71,933)	54,912
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	44,035	(147,604)
OTHER COMPREHENSIVE INCOME/(LOSS) THAT MAY BE RECLASSIFIED TO PROFIT OR LOSS IN SUBSEQUENT PERIODS		
Change in fair value of equity investments at fair value through other comprehensive income	(8,121)	5,200
Change in fair value of equity investments at fair value through profit or loss	1,218	(780)
Net other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods	(6,903)	4,420
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	37,132	(132,459)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	1,906,627	2,621,123
Attributable to:		
Non-controlling interests	1,622,372	2,385,072
Equity holders of the Company	284,255	236,051
Total	1,906,627	2,621,123

Interim Condensed Consolidated

Financial Position

30 June 2022

	Notes	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	13	13,890,670	13,011,818
Intangible assets		2,634,025	2,569,796
Goodwill		9,933,642	9,399,987
Investments in subsidiaries		12,555,179	11,610,712
Investments in associates		299,227	282,837
Equity investments in associates and joint ventures		22,835,121	22,343,990
Financial assets at fair value through profit or loss		21,795	29,916
Financial assets at fair value through other comprehensive income		1,634,964	1,206,489
Deferred tax assets		320,388	265,589
Prepaid expenses and deposits		77,469	77,395
Other non-current assets		2,414,451	2,013,740
Total non-current assets		66,616,931	62,812,269
CURRENT ASSETS			
Investments		6,143,790	5,472,315
Prepaid expenses and deposits	14	7,292,310	6,045,460
Receivables		3,038,152	3,466,043
Financial assets at fair value through profit or loss		2,386,620	4,241,069
Equity investments in associates and joint ventures		554,168	427,884
Cash and cash equivalents		12,258,061	10,308,157
Total current assets		31,673,101	29,960,928
Assets		463,705	463,705
Total assets		32,136,806	30,424,633
CURRENT LIABILITIES			
Prepaid expenses and deposits	15	5,707,081	5,063,661
Payables		6,621,586	7,020,048
Interest-bearing liabilities	16	17,569,068	15,460,243
Liabilities in respect of share-based payments		170,838	141,496
Contract liabilities		1,207,096	1,150,274
Other current liabilities		691,691	474,223
Total current liabilities		31,967,360	29,309,945
NET CURRENT ASSETS		169,446	1,114,688
TOTAL ASSETS LESS CURRENT LIABILITIES		66,786,377	63,926,957

Interim Condensed Consolidated

Financial Position

30 June 2022

	Notes	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
NON-CURRENT LIABILITIES			
Long-term borrowings	16	12,033,558	9,049,069
Lease liabilities		687,975	648,360
Deferred tax liabilities		3,273,451	3,129,746
Contract liabilities		176,007	239,011
Deferred interest		520,014	512,806
Other non-current liabilities		2,412,002	2,029,287
Total non-current liabilities		19,103,007	15,608,279
Net assets		47,683,370	48,318,678
EQUITY			
Equity attributable to owners of the parent			
Reserves		2,562,899	2,562,899
Retained earnings		35,585,198	36,572,163
		38,148,097	39,135,062
Non-controlling interests		9,535,273	9,183,616
Total equity		47,683,370	48,318,678

Interim Condensed Consolidated

Change in Equity

For the interim period ended 30 June 2022

Attributable to owners of the parent

	Share capital RMB'000	Share premium RMB'000	Fair value reserve RMB'000	Statutory surplus reserve RMB'000	Other reserve RMB'000	Exchange fluctuation reserve RMB'000	Retained profits RMB'000	Total RMB'000	Non- controlling interests RMB'000	Total equity RMB'000
At 1 January 2022 (Audited)	2,562,899	11,385,162*	203,703*	2,826,306*	2,784,724*	(1,457,965)*	20,830,233*	39,135,062	9,183,616	48,318,678
Profit for the period	—	—	—	—	—	—	1,553,504	1,553,504	315,991	1,869,495
Change in fair value of investment in subsidiaries	—	—	(6,471)	—	—	—	(6,471)	(6,471)	(432)	(6,903)
Share-based payment	—	—	(71,885)	—	—	—	(71,885)	(71,885)	—	(71,885)
Exchange difference	—	—	—	—	—	147,224	—	147,224	(31,304)	115,920
At 30 June 2022	—	—	(78,356)	—	—	147,224	1,553,504	1,622,372	284,255	1,906,627
At 1 July 2021 (Audited)	—	—	—	—	(1,150,544)	—	—	(1,150,544)	(74,382)	(1,224,926)
At 1 July 2021 (note 17)	—	—	—	—	—	—	—	—	196,369	196,369
Exchange difference	—	—	—	—	—	—	—	—	1,360	1,360
Dividend received from subsidiaries	—	—	—	—	4,922	—	4,922	4,922	11,421	16,343
Dividend received from subsidiaries	—	—	—	—	(9,435)	—	(9,435)	(9,435)	—	(9,435)
Capital increase of subsidiaries	—	—	—	—	—	—	—	—	23,151	23,151
Dividend received from subsidiaries	—	—	—	—	—	—	—	—	(141,048)	(141,048)
Dividend received from subsidiaries	—	—	—	—	—	—	—	—	(15,420)	(15,420)
Exchange difference	—	—	—	—	—	—	—	—	61,756	61,756
Fair value change of investment in subsidiaries	—	—	—	—	(28,381)	—	(28,381)	(28,381)	2,020	(26,361)
Share-based payment	—	—	—	—	9,566	—	9,566	9,566	2,175	11,741
Financial 2021 share-based payment (note 11)	—	—	—	—	—	—	(1,435,465)	(1,435,465)	—	(1,435,465)
Share-based payment of subsidiaries	—	—	(33,142)	—	—	—	33,142	—	—	—
At 30 June 2022 (Audited)	2,562,899	11,385,162*	92,205*	2,826,306*	1,610,852*	(1,310,741)*	20,981,414*	38,148,097	9,535,273	47,683,370

* The share-based payment is measured at the fair value of the equity instruments granted. MB 35,585,198,000 (31 December 2021: MB36,572,163,000) is the liability for the share-based payment.

Interim Condensed Consolidated

Charter of the E...
For the six months ended 30 June 2022

	Assets and Liabilities									
	Assets		Liabilities		Fair Value		Assets		Liabilities	
	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000
At 1 Jan 2021 (Audited)	2,562,899	11,385,162*	139,710*	2,728,604*	3,888,329*	(1,061,719)*	17,295,662*	36,938,647	8,988,749	45,927,396
Change in fair value of assets and liabilities							2,482,373	2,482,373	271,209	2,753,582
Change in fair value of assets			2,698					2,698	1,722	4,420
Change in fair value of liabilities			64,833					64,833		64,833
Exchange rate differences						(164,832)		(164,832)	(36,880)	(201,712)
At 31 Dec 2021			67,531			(164,832)	2,482,373	2,385,072	236,051	2,621,123
Change in fair value of assets and liabilities					(460,551)			(460,551)	(67,129)	(527,680)
Change in fair value of assets									9,600	9,600
Change in fair value of liabilities									169,710	169,710
Change in fair value of assets and liabilities					9,104			9,104	37,128	46,232
Change in fair value of assets					(17,557)			(17,557)		(17,557)
Change in fair value of liabilities									35,420	35,420
Change in fair value of assets and liabilities									(65,723)	(65,723)
Change in fair value of assets				(2,449)			2,449		(175,821)	(175,821)
Change in fair value of liabilities									58,179	58,179
Change in fair value of assets and liabilities					6,469			6,469	(4,166)	2,303
Change in fair value of assets					45,862			45,862	13,540	59,402
Change in fair value of liabilities									(1,102,997)	(1,102,997)
At 30 Jun 2022 (Audited)	2,562,899	11,385,162*	207,241*	2,726,155*	3,471,656	(1,226,551)*	18,677,487*	37,804,049	9,235,538	47,039,587

* The fair value of assets and liabilities is based on the fair value of the assets and liabilities at the end of the period. The fair value of the assets and liabilities at the end of the period is based on the fair value of the assets and liabilities at the end of the period.

Interim Condensed Consolidated

Cash Flow

For the six months ended
30 June 2022

		For the six months ended 30 June	
		2022 RMB'000 (Unaudited)	2021 MB'000 (Unaudited)
	Notes		
Cash generated from operations		2,221,854	2,094,337
Less: cash used in operations		(401,483)	(387,696)
Net cash inflow from operations		1,820,371	1,706,641
CASH FLOWS FROM INVESTING ACTIVITIES			
Purchase of property, plant and equipment		(2,595,334)	(2,286,070)
Acquisition of subsidiaries	17	(459,451)	(21,391)
Purchase of intangible assets		(239,719)	(100,172)
Purchase of financial assets at fair value through profit or loss		(252,071)	(191,752)
Disposal of subsidiaries		6,581	537,242
Disposal of financial assets at fair value through profit or loss		1,256,217	80,764
Disposal of intangible assets	18	704,493	237,609
Dividend received from subsidiaries		55,719	61,154
Dividend received from financial assets at fair value through profit or loss		32,175	8,009
Interest received from financial assets at fair value through profit or loss		103,686	18,421
Interest received from subsidiaries		(25,000)	(12,392)
Interest received from financial assets at fair value through profit or loss		(1,310,390)	(819,125)
Interest received from subsidiaries		161,366	6,509
Interest received from financial assets at fair value through profit or loss		76,573	31,450
Net cash outflow from investing activities		(2,485,155)	(2,449,744)

Interim Condensed Consolidated



Ca h Fl

For the six months ended 30 June 2022

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Unaudited)
CASH FLOWS FROM FINANCING ACTIVITIES		
Net cash generated from financing activities	17,847,543	14,234,577
Interest received	(12,918,555)	(12,719,442)
Interest paid	(448,224)	(419,549)
Dividends received	(88,200)	(68,914)
Capital raised from the issuance of shares	41,508	251,362
Dividends paid	(1,335,223)	
Dividends received from subsidiaries	(74,686)	(69,024)
Acquisition of subsidiaries	(1,088,182)	(530,770)
Bank borrowings	411,520	
Change in cash and cash equivalents	72,683	91,429
Net cash and cash equivalents at the end of the period	2,420,184	769,669
Net cash and cash equivalents at the beginning of the period	1,755,400	26,566
Change in cash and cash equivalents	6,450,650	7,324,881
Effect of exchange rate changes	68,077	(103,270)
Change in cash and cash equivalents	8,274,127	7,248,177
Analysis of balances of cash and cash equivalents:		
Cash and cash equivalents	12,258,061	10,489,133
Less: Less than 12 months maturity	(3,983,934)	(3,240,956)
Cash and cash equivalents	8,274,127	7,248,177

30 J 2022





ha hai F ha a - t al (Gr) C ., L. (h C) a - a li h a a j i i h li i
lia ili 31 Ma 1995 i h C. h C A ha ha ha - e li h ha t hai E ha - i - 7
A t 1998. h C t H ha ha ha - e li h Mai B ar h E ha - H K Li i (h
H t K t E ha -) i - 30 t - 2012. h a i t i r 31 De - e 1998, i - i i .

h₂hli h₂C i ha hai F Hi h h l (Gr) C L (F Hi h h h) h₂
 li a hli h₂C i F l a al Hli Li i h₂li a lli ha hli r
 h₂C i Mr. G G a ha .

D r i h e i h e 30 J e 2022 (h e e r i), h e G r a r i i a l l e a e i t h e e v e l e t ,
a a t e a a l e h a r a e i a l a e i a l e i n e t , i n t a e n t e i a l e i n e t a
h e n t j i t e l a e a h e r l i e f j e a i y e t a a e t

30 J. 2022 ha. 31 D. 2021.

[illegible]

A			HKF	3
A			HKA	16

Reference to the Conceptual Framework

he a lea i na he le i HKF a le e ri e el :

- [illegible]

HKF 9 Financial Instruments: latri he he he ha a he i i l he he a he i ha he he he he a

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

HKF 16 Leases: The Group has adopted HKF 16 Leases from 1 January 2022.

() (C)

HKF 16 Leases: The Group has adopted HKF 16 Leases from 1 January 2022. The Group has also adopted HKF 16 Leases from 1 January 2022. The Group has also adopted HKF 16 Leases from 1 January 2022.

4. OPERATING SEGMENT INFORMATION

For a more detailed description of the Group's operating segments, please refer to the Group's annual report for the year ended 31 December 2021.

(a) The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

() The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

() The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

() The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

(a) The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

Management has determined the Group's operating segments based on the internal financial information that is used for internal management purposes. The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

The Group's operating segments are as follows: (i) Pharmaceutical Products; (ii) Chemicals; (iii) Healthcare; (iv) Other.

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2022 (unaudited)

	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Eliminations RMB'000	Total RMB'000
Segment revenue:							
Pharmaceutical manufacturing	14,270,930	4,034,954	2,916,662	—	52,060	—	21,274,606
Medical devices and medical diagnosis	140,363	214,035	43,313	—	9,334	(407,045)	—
Segment revenue	14,411,293	4,248,989	2,959,975	—	61,394	(407,045)	21,274,606
Segment results*							
Pharmaceutical manufacturing	1,889,837	439,669	(386,703)	—	41,388	(20,930)	1,963,261
Medical devices and medical diagnosis	103,862	11,334	15,396	—	11,013	—	141,605
Healthcare Service	302,498	301,515	47,933	—	—	—	651,946
Pharmaceutical distribution and retail	83,261	7,596	12,901	—	110	(5,711)	98,157
Other business operations	(105,897)	(14,518)	(89,415)	—	(4,325)	49,853	(164,302)
Eliminations	(229,699)	(28,089)	(19,820)	—	14,642	305	(262,661)
Segment results	(96,979)	—	—	—	(2,585)	—	(99,564)
Assets	14,208	93,494	(16,446)	919,864	(112,537)	—	898,583
Segment assets	1,961,091	811,001	(436,154)	919,864	(52,294)	23,517	2,378,581
Liabilities	(382,366)	(111,764)	(5,670)	—	(23)	—	(499,823)
Segment liabilities	1,578,725	699,237	(441,824)	919,864	(52,317)	23,517	1,869,495
Segment assets:	51,748,370	10,007,104	11,108,724	16,774,252	5,021,141	(2,539,162)	92,120,429
Investments in joint ventures	290,610	—	832	—	7,785	—	299,227
Investments in associates	1,318,013	1,250,089	893,241	16,774,252	2,599,526	—	22,835,121
Segment assets	6,633,308	98,753,737	17,215,822	33,854,545	51,070,367	—	172,527,779
Segment liabilities:	22,453,057	3,539,092	5,408,677	—	1,497,902	(15,682,906)	17,215,822
Other segment information:							
Depreciation and amortization	722,087	115,279	206,588	—	20,372	—	1,064,326
Capital expenditures	65,473	20,319	11,628	—	—	—	97,420
Capital expenditures*	1,800,755	155,846	196,281	—	21,210	—	2,174,092

* The capital expenditures include the purchase of property, plant and equipment, intangible assets, and investments in joint ventures and associates.

** Capital expenditures include the purchase of property, plant and equipment, intangible assets, and investments in joint ventures and associates, and the purchase of financial assets.

Note: The capital expenditures include the purchase of property, plant and equipment, intangible assets, and investments in joint ventures and associates, and the purchase of financial assets.

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2021 (unaudited)

	Pharmaceutical MB'000	Medical device MB'000	Health care MB'000	Pharmaceutical MB'000	Health care MB'000	Other MB'000	Elimination MB'000	MB'000
Segment revenue:								
Pharmaceutical	12,179,257	2,832,211	1,843,434		22,635			16,877,537
Health care	13,233	17,779	20,501		12,639	(64,152)		
Elimination	12,192,490	2,849,990	1,863,935		35,274	(64,152)		16,877,537
Segment results*								
Pharmaceutical	1,352,891	434,099	(19,393)		9,266	(23,352)		1,753,511
Health care	102,012	14,123	15,428		7,430			138,993
Pharmaceutical	201,990	2,283	87,416		262,270	(111,725)		442,234
Health care	85,180	16,516	14,508		1,698	(14,636)		103,266
Pharmaceutical	(80,436)	(13,698)	(25,545)		(5,312)	21,894		(103,097)
Health care	(35,582)	(34,764)	(12,181)		(258,830)			(341,357)
Health care	(93,805)				(12)			(93,817)
Pharmaceutical	35,707	90,143	(28,178)	896,991	(69,037)			925,626
Elimination								478,870
Pharmaceutical	1,567,957	508,702	32,055	896,991	(52,527)	(127,819)		3,304,229
Health care	(311,399)	(54,486)	(47,288)		(2)			(413,175)
Elimination								(137,472)
Pharmaceutical	1,256,558	454,216	(15,233)	896,991	(52,529)	(127,819)		2,753,582
Segment assets:								
Pharmaceutical	46,659,269	8,322,272	9,898,810	15,355,639	4,458,138	(2,668,056)		82,026,072
Investments in joint ventures	342,929				6,148			349,077
Investments in associates	2,273,758	555,078	1,589,874	15,355,639	2,673,511			22,447,860
Elimination								6,396,412
Pharmaceutical								88,422,484
Segment liabilities:								
Pharmaceutical	17,422,127	2,202,799	2,555,456		710,137	(10,426,621)		12,463,898
Elimination								28,918,999
Pharmaceutical								41,382,897
Other segment information:								
Depreciation and amortization	643,074	123,971	157,392		21,010			945,447
Impairment loss on investments	(1,288)	25,438	7,872		190,114			222,136
Capital expenditure**	1,323,129	137,508	477,910		102,565			2,041,112

* Segment results are calculated based on the management's internal reporting system, which is consistent with the consolidated financial statements.

** Capital expenditure includes the purchase of property, plant and equipment, intangible assets, and investments in subsidiaries and associates.

Note: The pharmaceutical segment includes the business of the Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

5. REVENUE

Accounting revenue information:

	For the six months ended	
	30 June	2021
	2022	2021
	RMB'000	MB'000
	(Unaudited)	(Unaudited)
Revenue from contracts with customer	21,258,760	16,864,028
Revenue from other sources	15,846	13,509
Grand total	21,274,606	16,877,537

Disaggregated revenue information for revenue from contracts with customer

For the six months ended 30 June 2022 (unaudited)

Segments	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare service RMB'000	Other business operations RMB'000	Total RMB'000
Types of goods or services					
Pharmaceutical products	13,844,207	3,915,452	441,291	—	18,200,950
Medical devices	418,473	89,828	2,472,638	41,175	3,022,114
Other services	6,625	29,071	—	—	35,696
Grand total	14,269,305	4,034,351	2,913,929	41,175	21,258,760
Geographical markets					
Mainland China	9,253,783	1,460,631	2,913,290	39,753	13,667,457
Overseas	5,015,522	2,573,720	639	1,422	7,591,303
Grand total	14,269,305	4,034,351	2,913,929	41,175	21,258,760
Timing of revenue recognition					
Goods transferred	13,850,832	3,944,523	441,291	—	18,236,646
Services transferred	276,437	33,096	2,472,638	41,175	2,823,346
Services transferred over time	142,036	56,732	—	—	198,768
Grand total	14,269,305	4,034,351	2,913,929	41,175	21,258,760

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

5. REVENUE (Continued)

Disaggregated revenue information for revenue from contracts with customers (Continued)

For the six months ended 30 June 2021 (unaudited)

	Pharmaceuticals MB'000	Medical devices MB'000	Health care MB'000	Health care MB'000	Total MB'000
Types of goods or services					
Pharmaceuticals	11,733,205	2,742,001	37,479		14,512,685
Medical devices	414,422	76,259	1,804,041	11,459	2,306,181
Health care	30,599	13,951	612		45,162
Geographical markets					
Mainland China	8,474,661	1,339,179	1,842,132	10,040	11,666,012
Overseas	3,703,565	1,493,032		1,419	5,198,016
Timing of revenue recognition					
Goods transferred at a point in time	11,763,804	2,755,952	38,091		14,557,847
Services transferred at a point in time	297,157	13,239	1,804,041	11,459	2,125,896
Services transferred over time	117,265	63,020			180,285
Total	12,178,226	2,832,211	1,842,132	11,459	16,864,028

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

6. OTHER INCOME

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Unaudited)
Dividend income from subsidiaries	36,451	8,009
Interest income from bank deposits	147,045	132,660
Government grants	149	1,045
	183,645	141,714

7. OTHER GAINS

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Unaudited)
Gain on disposal of subsidiaries	186,594	279,501
Fair value gain on disposal of subsidiaries	—	1,230,308
Gain on disposal of intangible assets	382,978	78,995
Gain on disposal of property, plant and equipment	81,532	56,451
	651,104	1,645,255

8. FINANCE COSTS

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Unaudited)
Interest expense on bank borrowings	444,244	413,098
Interest expense on lease liabilities	22,647	14,841
Lease interest expense	(28,704)	(7,214)
	438,187	420,725

30 JUN 2022

h-e Gr i -e a i a r r i -e a a -e r ha r i / (e i i) :

[illegible]

10. INCOME TAX

The Group is subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%). The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC. The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC. The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC.

The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC. The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC. The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC. The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC.

The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC. The Group is also subject to the Corporate Income Tax at the rate of 25% (the rate applicable to the Group for the six months ended 30 June 2021: 25%) in the PRC.

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
Current tax	603,241	451,937
Deferred tax	(94,155)	98,710
Total tax expense	509,086	550,647

11. DIVIDENDS

The Board has declared a dividend of RMB0.56 (a dividend of MB0.56) per share for the six months ended 30 June 2022 (the dividend for the six months ended 30 June 2021: Nil).

The dividend of RMB0.56 (a dividend of MB0.56) per share for the six months ended 30 June 2022 (the dividend for the six months ended 30 June 2021: Nil) is payable on 31 December 2021 to the shareholders of the Group as at the record date of 30 June 2022.

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

The diluted earnings per share attributable to ordinary equity holders of the parent is calculated by dividing the net profit attributable to ordinary equity holders of the parent by the weighted average number of diluted ordinary shares outstanding during the period. For the six months ended 30 June 2021: 2,562,898,545 (the same as the basic earnings per share).

The diluted earnings per share attributable to ordinary equity holders of the parent is calculated by dividing the net profit attributable to ordinary equity holders of the parent by the weighted average number of diluted ordinary shares outstanding during the period. For the six months ended 30 June 2022, the diluted earnings per share attributable to ordinary equity holders of the parent is RMB1.553,504 (unaudited), which is the same as the basic earnings per share.

The diluted earnings per share attributable to ordinary equity holders of the parent is calculated by dividing the net profit attributable to ordinary equity holders of the parent by the weighted average number of diluted ordinary shares outstanding during the period.

	For the six months ended 30 June	
	2022 RMB'000 (unaudited)	2021 MB'000 (audited)
Earnings		
Net profit attributable to ordinary equity holders of the parent	1,553,504	2,482,373
Net profit attributable to ordinary equity holders of the parent, adjusted for the effect of dilutive potential ordinary shares	1,553,504	2,482,373

	Number of shares For the six months ended 30 June	
	2022 (unaudited)	2021 (audited)
Shares		
Weighted average number of ordinary shares outstanding during the period	2,562,898,545	2,562,898,545
Weighted average number of diluted ordinary shares outstanding during the period	2,562,898,545	2,562,898,545

The Group has no dilutive potential ordinary shares outstanding as at 30 June 2022.

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

13. PROPERTY, PLANT AND EQUIPMENT

	For the six months ended	
	30 June	
	2022	2021
	RMB'000	MB'000
	(Unaudited)	(Unaudited)
Carrying value at 1 January	13,011,818	12,579,873
Additions	1,552,693	1,481,681
Disposals	44,342	790
Depreciation	(21,878)	(46,840)
Depreciation expense	(78,349)	(1,434,727)
Depreciation expense	(609,401)	(564,429)
Exchange differences	(8,555)	(29,439)
Carrying value at 30 June	13,890,670	11,986,909

The Group's property, plant and equipment is measured at cost less accumulated depreciation and impairment losses. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets. The estimated useful lives are as follows:

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

14. TRADE AND BILLS RECEIVABLES (Continued)

Accounts receivable and bills receivable are classified into various categories based on the nature of the goods or services provided.

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Accounts receivable:		
1 year	7,264,653	6,050,772
1 to 2 years	109,643	129,356
2 to 3 years	91,882	55,349
over 3 years	125,877	120,136
	7,592,055	6,355,613
Less: provision for impairment	(319,488)	(326,380)
	7,272,567	6,029,233

As at 30 June 2022, trade receivables and bills receivable had a carrying amount of RMB99,940,000 (31 December 2021: MB69,444,000) which are classified as non-current assets.

15. TRADE AND BILLS PAYABLES

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Trade payables	4,862,147	4,515,273
Bills payable	844,934	548,388
	5,707,081	5,063,661

Trade and bills payable are classified into various categories based on the nature of the goods or services received.

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

15. TRADE AND BILLS PAYABLES (Continued)

As at the end of the reporting period	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Trade payables	4,758,515	4,466,889
1 year	79,408	26,002
2 years	13,503	14,949
over 3 years	10,721	7,433
	4,862,147	4,515,273

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

	Notes	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Bank borrowings	(1)	1,494,670	1,402,634
Other borrowings		24,423,015	18,220,425
		25,917,685	19,623,059
Financial guarantees	(2)	600,000	1,200,000
Contract liabilities	(3)	3,084,941	3,686,253
		29,602,626	24,509,312
Liabilities for interest		(17,569,068)	(15,460,243)
Net interest-bearing		12,033,558	9,049,069

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

As at 30 June 2022, the Group's interest-bearing bank and other borrowings are as follows:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Bank loans:		
- short-term	17,569,068	15,460,243
- 1 to 2 years	4,444,947	4,875,505
- 2 to 5 years	5,451,125	1,787,641
- over 5 years	2,137,486	2,385,923
	29,602,626	24,509,312
Other financial liabilities	(17,569,068)	(15,460,243)
Net interest-bearing	12,033,558	9,049,069

Notes:

(1) Bank loans

The bank loans are secured by assets and are subject to interest rates ranging from 0.3000% to 4.8300% (31 December 2021: 0.3000% to 6.0000%) and are classified as follows:

As at 30 June 2022, the Group's bank loans are classified as follows: (a) short-term bank loans of RMB 771,550,000 (31 December 2021: MB550,040,000), which are classified as current liabilities; (b) bank loans with a term of 1 to 2 years of RMB 511,229,000 (31 December 2021: MB513,993,000), which are classified as non-current liabilities.

As at 30 June 2022, the Group's bank loans are classified as follows: (c) bank loans with a term of 2 to 5 years of RMB 99,940,000 (31 December 2021: MB69,444,000), which are classified as non-current liabilities; (d) bank loans with a term of over 5 years of RMB 8,417,000 (31 December 2021: MB8,296,000), which are classified as non-current liabilities.

As at 30 June 2022, the Group's bank loans are secured by assets and are subject to interest rates ranging from 0.3000% to 4.8300% (31 December 2021: 0.3000% to 6.0000%) and are classified as follows:

As at 30 June 2022, the Group's bank loans are secured by assets and are subject to interest rates ranging from 0.3000% to 4.8300% (31 December 2021: 0.3000% to 6.0000%) and are classified as follows:

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

Notes: (Continued)

(2) Super Short-term Commercial Paper

13 April 2022, the Company issued super short-term commercial paper with a term of 11 days, a principal amount of RMB600,000,000, and an interest rate of 2.65%.

(3) Corporate bonds

13 April 2018, the Company issued corporate bonds with a term of 3 years, a principal amount of RMB1,300,000,000, and an interest rate of 3.50%.

30 November 2018, the Company issued corporate bonds with a term of 3 years, a principal amount of RMB500,000,000, and an interest rate of 3.50%.

2 February 2021, the Company issued corporate bonds with a term of 3 years, a principal amount of RMB1,600,000,000, and an interest rate of 3.98%.

9 March 2022, the Company issued corporate bonds with a term of 3 years, a principal amount of RMB500,000,000, and an interest rate of 3.50%.

17. BUSINESS COMBINATION

20 January 2022, the Company acquired 70% of the equity of Xihi Hospital (Guangzhou Xishi Hospital) (Xihi Hospital) for a consideration of RMB 809,200,000.

* The Company has acquired 70% of the equity of Xihi Hospital (Guangzhou Xishi Hospital) (Xihi Hospital) for a consideration of RMB 809,200,000.

Notes to Interim Condensed Consolidated
Financial Statements

30 June 2022

17. BUSINESS COMBINATION (Continued)

The fair value of the identifiable intangible assets acquired in the business combination is determined based on the following assumptions:

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

18. DISPOSAL OF SUBSIDIARIES

During the period from 1 January 2022 to 30 June 2022, the Group has disposed of its subsidiaries. The disposal of the subsidiary Hainan Aima Medical Co., Ltd. (海南艾瑪藥業股份有限公司) has resulted in a net gain of RMB125,328,000. The disposal of the subsidiary Jiangsu Huanghe Pharmaceutical Co., Ltd.* (江蘇黃河藥業股份有限公司) has resulted in a net gain of RMB125,328,000. The disposal of the subsidiary Jiangsu Huanghe Pharmaceutical Co., Ltd.* (江蘇黃河藥業股份有限公司) has resulted in a net gain of RMB125,328,000.

During the period from 1 January 2022 to 30 June 2022, the Group has disposed of its subsidiaries. The disposal of the subsidiary Shanghai Hui Xue Biotechnology Co., Ltd. (上海輸血技術有限公司) has resulted in a net gain of RMB390,000,000. The disposal of the subsidiary Shanghai Hui Xue Biotechnology Co., Ltd. (上海輸血技術有限公司) has resulted in a net gain of RMB390,000,000.

*

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

18. DISPOSAL OF SUBSIDIARIES (Continued)

As at the end of the reporting period, the following subsidiaries are disposed:

	MB'000
Cash consideration received from the disposal	421,905
Cash consideration received from the disposal of the subsidiary	319,220
Cash consideration received from the disposal of the subsidiary	(36,632)
Net cash consideration received from the disposal of the subsidiary	704,493

19. COMMITMENTS

The Group has the following commitments at the end of the reporting period:

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Contractual commitments:		
Contractual commitments, including the disposal of the subsidiary	2,415,887	2,127,421
Contractual commitments, including the disposal of the subsidiary	2,487,233	2,066,497
Contractual commitments, including the disposal of the subsidiary	513,177	451,933
Contractual commitments, including the disposal of the subsidiary		
Contractual commitments, including the disposal of the subsidiary	2,544,064	3,128,531
Contractual commitments, including the disposal of the subsidiary	7,960,361	7,774,382

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS

(a) Sales of pharmaceutical products and services

	For the six months ended	
	30 June	
	2022	2021
	RMB'000	MB'000
	(Unaudited)	(Unaudited)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 6 & 15)	2,210,042	1,809,891
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 16)	365,650	326,501
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8)	11,744	40
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Li Jie, Chairman) (notes 1 & 4)	4,670	5,139
Fosun Biopharmaceutical Co., Ltd. (notes 2 & 4)	3,222	2,030
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	2,930	7,936
Fosun Pharmaceutical (Group) Co., Ltd. (notes 3 & 4 & 10 & 16)	2,749	252
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Li Jie, Chairman) (notes 1 & 4)	2,335	2,436
Jiayuan Pharmaceutical Co., Ltd. (notes 1 & 4)	537	1,251
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Haohai) Co., Ltd. (notes 1 & 4)	447	6
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 6)	179	2,039
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 2 & 4)	123	671
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8)	57	
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Haohai) Co., Ltd. (notes 4 & 7)	19	19
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	10	26
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8 & 17)	5	6
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 18)	—	637
Glaucoside Co., Ltd. (notes 4 & 8 & 19)	—	148
Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8)	—	4
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	—	3
	2,604,719	2,159,035

30 June 2022

(b) Purchase of pharmaceutical products and services

(c) Leasing and property management services

The diagram illustrates a rectangular area divided into three vertical sections. The left and right sections are white, and the middle section is light blue. The middle section is further divided into three horizontal sections by two thin blue lines. The top and bottom sections of the middle section are light blue, and the middle section is white.

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

As lessee

For the six months ended 30 June 2022

Types of leased assets	Rental charges for short-term/low-value assets leases	Additions of right-of-use assets
For the six months ended 30 June 2022		
For the six months ended 30 June 2022	9,454	23,569

For the six months ended 30 June 2021

Types of leased assets	Rental charges for short-term/low-value assets leases	Additions of right-of-use assets
For the six months ended 30 June 2021		
For the six months ended 30 June 2021	5,242	
For the six months ended 30 June 2021	114	
For the six months ended 30 June 2021	41	
	5,397	

For the six months ended
30 June

Property management services	2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
For the six months ended 30 June 2022	11,732	6,818

30 June 2022

(d) Loans from/to a related parties

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Deposits in Fosun Finance		
Financial assets (notes 3 & 16)	870,551	974,576

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Loans from Fosun Finance		
Financial assets (notes 3 & 16)	111,686	116,127

ha hai F har a e i al Devel C , L . j e a i ve ear l a MB188,840,000 F Ki
Bi l i al e h l C , L . h i e e t e r a e i 10% h i h e t h a h e e h a r i e e t r a e r h e a e e r i .
A h e , MB33,781,000 i r 12 e r 2017 12 e r 2022, MB33,781,000 i r 5 F e r a r
2018 12 e r 2022, MB50,395,000 i r 15 Ma 2019 15 Ma 2022, MB70,883,000 i r 17
e r 2019 16 e r 2022.D ri hi ri , h e Gr e e l e v e h e l a e a e e MB50,395,000.00.
A a 30 J e 2022, h e l a ri i al i MB 138,445,000(31 D e e e r 2021: MB 188,840,000), a h e l a
i e e t e e l e i MB 113,000(31 D e e e r 2021: MB 301,000).

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Financial liabilities (note 2)	138,558	189,141

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

Loans to Nature's Sunshine (Far East) Limited

Far East Natural Co., Ltd. 借出 1,927,000 美元 (Nature's Sunshine (Far East) Limited) 于 2021 年 12 月 31 日。该贷款于 2021 年 12 月 31 日到期。2022 年 6 月 30 日，该贷款余额为 1,927,000 美元。

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Nature's Sunshine (Far East) Limited (note 1)	—	1,927

Loans to StarKids Children's Hospital Shanghai

上海星孩儿童医院管理有限公司 借出 9,385,000 美元 (StarKids Children's Hospital Shanghai) 于 2021 年 12 月 31 日。该贷款于 2021 年 12 月 31 日到期。2022 年 6 月 30 日，该贷款余额为 9,564,000 美元 (2021 年 12 月 31 日：9,385,000 美元)。

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
StarKids Children's Hospital Shanghai (note 1)	9,564	9,385

Loans to Shanghai Xingmai Information Technology Co., Ltd.

上海兴迈信息技术有限公司 借出 73,264 美元 (Shanghai Xingmai Information Technology Co., Ltd.) 于 2021 年 12 月 31 日。该贷款于 2021 年 12 月 31 日到期。2022 年 6 月 30 日，该贷款余额为 73,264 美元 (2021 年 12 月 31 日：73,264 美元)。

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Shanghai Xingmai Information Technology Co., Ltd. (note 1)	—	73,264

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

Loans from Shanghai Youle Information Technology Co., Ltd.

Shanghai Youle Information Technology Co., Ltd. provided a loan of RMB5,492,000 to Foshan Hualihang (Group) Co., Ltd. at an annual interest rate of 4.35%. The loan was repaid on 19 June 2021. As at 30 June 2022, the loan balance was RMB160,000 (31 December 2021: RMB40,000).

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Shanghai Youle Information Technology Co., Ltd. (note 3)	5,652	5,532

Loans from Shanghai Fosun High Tech (Group) Company limited

Shanghai Fosun High Tech (Group) Company limited provided a loan of RMB18,673,000 to Foshan Hualihang (Group) Co., Ltd. at an annual interest rate of 4.35%. The loan was repaid on 19 June 2021. As at 30 June 2022, the loan balance was RMB543,000 (31 December 2021: RMB137,000).

	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
Shanghai Fosun High Tech (Group) Company limited (note 3)	19,216	18,810

(e) Interest income from/interest expense to related parties

	Six months ended 30 June 2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
Interest income		
Foshan Kite Biomedical Co., Ltd. (note 2)	4,248	4,678
Foshan Financial (notes 3 & 16)	4,026	4,560
Shanghai Chilte' Hualihang (note 1)	180	182
Nanjing Chilte' Hualihang (Fair Earnings) Li (note 1)	14	112
	8,468	9,532

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (Continued)

The interest rate for the financial assets and liabilities are the same as the interest rate for the financial assets and liabilities. The interest rate for the financial assets and liabilities is 0.35% (For the period ended 30 June 2021: 0.35%), the interest rate for the financial liabilities is 1.485%-1.89% (For the period ended 30 June 2021: 1.89%), the interest rate for the financial liabilities is 1.15% (For the period ended 30 June 2021: 1.15%), and the interest rate for the financial liabilities is 1.55%-1.755% (For the period ended 30 June 2021: 1.55%-1.755%).

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
Interest expense		
Financial (notes 3 & 16)	2,666	1,432
Ha Hai Financial Holding (Group) Co., Ltd. (notes 3 & 16)	406	
Ha Hai Financial Holding Co., Ltd. (notes 3 & 16)	119	
	3,191	1,432

Notes:

- The interest rate for the financial assets and liabilities is 0.35%.
- The interest rate for the financial liabilities is 1.485%-1.89%.
- The interest rate for the financial liabilities is 1.15%.
- The interest rate for the financial liabilities is 1.55%-1.755%.
- The interest rate for the financial assets and liabilities is 0.35%.
- The interest rate for the financial liabilities is 1.485%-1.89%.
- The interest rate for the financial liabilities is 1.15%.
- The interest rate for the financial liabilities is 1.55%-1.755%.
- In April 2021, the Company entered into a financial arrangement with Ha Hai Financial Holding Co., Ltd. for the period ended 30 June 2021.

Final trial

Notes: (Continued)

(11) D ri hi , h e Gr f e a l y e a f e j e f h e F I a i a l L i a i i a r i e a r j i e . h e
F I a i a l L i a i i a r i e I e h a h a i F H i h e h (Gr) C l i e . , H a i a F i a i C . , L . ,
H a i a F i I a i a l B i e a r C . , L . , a r C l (H a h) C h a i M a a e C a r C l (i)
C h a i M a a e C L . , h a h a i j i l i f a h l C . , h a h a i X i i H a h M a a e C L . ,
h a h a i X i j i E e M a a e C L . , h a i F i C L . , h a i F i i h i B i e C L . ,
C . , L . , h a h a i F H a I a i a l a e C . , L . , H a i a F i I a i a l L i j i C . , L . , h a h a i X i i H a

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(g) Donations

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (Audited)
Share-based payments	7,502	8,708

For the six months ended 30 June 2022, the Group received donations of RMB7,502,000 (for the six months ended 30 June 2021: RMB8,708,000) from various shareholders and other related parties.

(h) Outstanding balances with related parties:

- As at 30 June 2022, the Group has a balance due to the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. of RMB1,705,659,000 (31 December 2021: RMB1,725,786,000). The balance is due to the Group for the purchase of raw materials and other services.
- As at 30 June 2022, the Group has a balance due to the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. of RMB1,016,575,000 (31 December 2021: RMB994,289,000). The balance is due to the Group for the purchase of raw materials and other services.
- As at 30 June 2022, the Group has a balance due to the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. of RMB143,923,000 (31 December 2021: RMB194,222,000). The balance is due to the Group for the purchase of raw materials and other services.
- As at 30 June 2022, the Group has a balance due to the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. of RMB11,869,000 (31 December 2021: RMB10,856,000). The balance is due to the Group for the purchase of raw materials and other services.
- As at 30 June 2022, the Group has a balance due to the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. of RMB216,497,000 (31 December 2021: RMB197,757,000). The balance is due to the Group for the purchase of raw materials and other services.
- As at 30 June 2022, the Group has a balance due to the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. of RMB312,662,000 (31 December 2021: RMB317,922,000). The balance is due to the Group for the purchase of raw materials and other services.
- As at 30 June 2022, the Group has a balance due to the Shanghai Fosun Pharmaceutical (Group) Co., Ltd. of RMB6,696,000 (31 December 2021: RMB6,696,000). The balance is due to the Group for the purchase of raw materials and other services.

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(h) Outstanding balances with related parties: (Continued)

(viii) As at 30 June 2022, the amount due to the related party is RMB107,000 (31 December 2021: RMB419,000) which is due to the related party for the purchase of goods.

(i) Certain liabilities of the Group are due to the related party for the purchase of goods. The amount due to the related party is RMB107,000 (31 December 2021: RMB419,000) which is due to the related party for the purchase of goods.

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The fair value of the financial assets and liabilities of the Group is determined by the fair value hierarchy, which is based on the inputs used in the valuation technique. The fair value hierarchy is as follows:

	Carrying amounts		Fair values	
	30 June 2022	31 December 2021	30 June 2022	31 December 2021
	RMB'000	MB'000	RMB'000	MB'000
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
Financial Assets:				
Equity investments at fair value	21,795	29,916	21,795	29,916
Debt investments at fair value	554,168	427,884	554,168	427,884
Financial assets at fair value	4,021,584	5,447,558	4,021,584	5,447,558
Financial liabilities at fair value	77,469	77,395	78,394	78,319
	4,675,016	5,982,753	4,675,941	5,983,677
Financial Liabilities:				
Non-current liabilities	10,787,707	6,694,183	10,690,730	6,599,603
Current liabilities (including lease liabilities)	3,084,941	3,686,254	3,084,632	3,654,328
Financial liabilities	2,342,067	1,944,174	2,342,067	1,944,174
	16,214,715	12,324,611	16,117,429	12,198,105

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

The Group's financial assets and liabilities are categorized into Level 1, Level 2 and Level 3 of the fair value hierarchy. The Group's financial assets and liabilities are categorized into Level 1, Level 2 and Level 3 of the fair value hierarchy. The Group's financial assets and liabilities are categorized into Level 1, Level 2 and Level 3 of the fair value hierarchy.

The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy.

The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy.

The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy.

Based on the fair value hierarchy, the fair value of the financial assets and liabilities is determined by using the fair value hierarchy.

Unobservable inputs for Level 3 assets

The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy.

The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy.

Unobservable inputs for Level 3 liabilities

The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy.

The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy. The fair value of the financial assets and liabilities is determined by using the fair value hierarchy.

Notes to Interim Condensed Consolidated

Financial Report

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy

The following table illustrates the fair value measurement hierarchy of the Group's financial instruments:

Assets measured at fair value:

As at 30 June 2022 (Unaudited)

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
Financial assets at fair value	1,924,337	389,335	1,707,912	4,021,584
Equity investments at fair value	4,073	17,722	—	21,795
Debt investments at fair value	—	554,168	—	554,168
	1,928,410	961,225	1,707,912	4,597,547

As at 31 December 2021 (Audited)

	Fair value measurement using Significant observable inputs (Level 1) MB'000	Significant unobservable inputs (Level 2) MB'000	Significant unobservable inputs (Level 3) MB'000	Total MB'000
Financial assets at fair value	3,259,068	573,994	1,614,496	5,447,558
Equity investments at fair value	5,380	24,536	—	29,916
Debt investments at fair value	—	427,884	—	427,884
	3,264,448	1,026,414	1,614,496	5,905,358

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

The following table shows the fair value of the assets measured at fair value at the end of the reporting period, categorized by the fair value hierarchy.

For the six months ended 30 June 2022

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
At 1 January 2022	1,614,496	—
Transfer from Level 1 to Level 2	(31,879)	—
Transfer from Level 2 to Level 1	121,970	—
Transfer from Level 1 to Level 3	42,586	—
At 30 June 2022	340,981	—
At 30 June 2022	(380,242)	—
At 30 June 2022	1,707,912	—

For the six months ended 30 June 2021

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
At 1 January 2021	1,614,496	—
Transfer from Level 1 to Level 2	(31,879)	—
Transfer from Level 2 to Level 1	121,970	—
Transfer from Level 1 to Level 3	42,586	—
At 30 June 2021	340,981	—
At 30 June 2021	(380,242)	—
At 30 June 2021	1,707,912	—

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)**Fair value hierarchy (Continued)**

Liabilities measured at fair value:

As at 30 June 2022 (Unaudited)

	Fair value measurement using			
	Quoted prices in active Markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
	RMB'000	RMB'000	RMB'000	RMB'000
Assets measured at fair value	—	—	2,152,663	2,152,663

As at 31 December 2021 (Audited)

	Fair value measurement using			
	Quoted prices in active Markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
	MB'000	MB'000	MB'000	MB'000
Assets measured at fair value	—	—	1,729,070	1,729,070

The fair value hierarchy is based on the inputs used in the valuation techniques applied to the assets or liabilities. The hierarchy is as follows:

30 JUN 2022

A a 30 J e 2022 a 31 D e e e 2021, h e G r i h a v e a i e l i a i l i e .

I J l 2022, h e C a i e 106,756,666 A- h a t e 10 r i e t i a - l i e r i a a i e r i e
MB42.00 h a t e, a h e t a l a r a i e a MB4,483,779,972.00. h e h a t e t i r a i r e t e
r h e e l i e A- h a t e t e a h e h a h a i B r a h C h i a e r i l e D e n i t a C l a r i
C r i r a i L i i e 27 J l 2022. h e e l i t e A- h a t e a t e r a a l e h a t e i h a l - r i . h e h a t e
r i e h e r i e t h a l l t e r a t e i h i 6 h r h e a e h e i h e i a e a t h e
r a e a l e r i i e r e t e h e r a i a i e r a e a t h e h e l - r i .

h₂i₂ri₂ e₂e₂ li₂a₂e₂ i₂a₂ial₂ t₂a₂e₂e₂t₂ e₂e₂a₂ri₂ ve₂a₂ a₂h₂ri₂e₂ ri₂e₂ t₂h₂e₂ar₂ Di₂e₂t₂r₂

Definitions

I		i h i i - e f r i t e n o r i , l e t h e t e s t t h e r i e k e i t e , t h e I l i t e r h a l l h a v e t h e c a i q u t d e .
%		m e t e t
ADC	A	t j - r C j a t e
Al a	Al a	L a r L y , a m p t e i t e i I r a l a a i i a r t h e C m
A e	A e	I . , a m p t e i t e i h e m i t e t a e , t h e h a t e h i h a t e l i t e t h e N A D A (t C : AMGN)
A ha te()	e i ha te()	t h e C m i h a i al va e MB1.00 ca h, hi h a t e li t e t h e h a hai t E ha ea t ra e i MB
A r i Le A ia i	t h e ar i Le a ia i	t h e C m
a ia e	ha t h e ca i	i ve t t e r t h e H K Li t le
A ralia	C	-eal t h A t ralia
BIC	B e	-i - la
Bi N e h r BN t e a:	3 e e 221054 15.748 0 (223 Bi N)	0.5(E ,) 0.5(, a m p) 0.5(t e i t e r) 0.6(e G t m) 0.5(t h 0.5(h e har th

Definitions

C C	Chi a -e ri i -e -e la r C i i * (中國證券監督管理委員會)
Di t -i ()	i t -i () t h C
D	Di t -i t a i t
E	E r a i
E r a r a	E r a r a La r a ri .A., a i i -e i i Brazil
FIC	Fi r -i - la
F ha Cha h -e H i al	F ha F Cha h -e H i al Li i -e * (佛山復星禪誠醫院有限公司), r -e i a F ha Cha h -e C -e r al H i al C Li i -e * (佛山市禪城區中心醫院有限公司), a i i a r t h C
F Dia i	F Dia i -e h l (ha hai) C ., L . * (復星診斷科技(上海)有限公司), a i i a r t h C
F Heal h	ha hai F Heal h -e h l (Gr C ., L . * (上海復星健康科技(集團)有限公司), r -e i a ha hai F Heal h a t -e (Gr C ., L . * (上海復星醫療(集團)有限 公司), a i i a r t h C
F Heal h Gr	F Heal h a i i i a r i e
F Heal h ha t -e i h -e	h -e t a -e -e h a t -e i -e i y -e h -e F Heal h a y -e F Heal h,),64 .5(hai)0.6(t Hea 464 -e -e i64 -e i028h -e), 2 J -e 1 h -e i 0 -e -e 171 l (Gr C ., L . * ()有限公司),

F Kijē	F Kijē Bi l i al ē h l C ., Lj .*(復星凱特生物科技有限公司), a j i t vē t ē hē C 𐄂𐄂
F har a ē i al l t rīal	ha hai F har a ē i al l t rīal D ē vēl 𐄂𐄂 ē t C 𐄂𐄂 Li i ē *(上海復星醫藥產業發展有限公司), a i i ar t hē C 𐄂𐄂
Gē i ē Bi t ē h	Hē a Gē i ē Bi t ē h C ., Lj .*(河南真實生物科技有限公司)
G 𐄂𐄂 har a	G 𐄂𐄂 har a (r i a ē) Li i ē a i i i ar G 𐄂𐄂 har a l t ē r a i al F -LLC
Gla har a	Gla har a Li i ē , a 𐄂𐄂 i r 𐄂𐄂 r a ē i l i a a a i i ar t hē C 𐄂𐄂 , t hē h a ē hi h a ē li t ē t hē B E a N E (t C ē: Gla)
Gla har a h a ē 𐄂 i l ē t vē hē ē	t hē h a ē 𐄂 i i ē i vē hē ē a 𐄂𐄂 Gla har a, t hē a 𐄂 i hi h a a a 𐄂𐄂 vē t hē h a ē h l ē r a t hē a al ē ē r al ē ē i t hē C 𐄂𐄂 hēl 25 J ē 2019 a t hē h a ē h l ē r F l t ē r a i al a t i a al ē ē r al ē ē i hēl 5 J ē 2019
GM	G Ma a t ē r a t i ē
Gr 𐄂 r ē	t hē C 𐄂𐄂 a i i i ar ē (t hē C 𐄂𐄂 a a ē r ē t ē i i i ar ē , a t hē t ē t a t ē i t ē)
G a har a	i 𐄂 har H l i G a har a C ., Lj .*(國藥控股國大藥房有限公司)
G ili har a	G ili har a ē i al C ., Lj .*(桂林南藥股份有限公司), a i i ar t hē C 𐄂𐄂
H h a ē()	vē ē a li t ē t ē h a ē() i hē r i ar h a ē a i al t hē C 𐄂𐄂 , i h a i al al ē MB1.00 ē h, hi h a ē li t ē t hē H K t E ha ē a t r a ē i H K llar
HKF	t hē H K Fi a i al ē 𐄂 t i t a ar
H K llar r HK llar	H K llar , hē la l r ē H K
H K Li i lē	t hē lē G vē i t hē Li i ē r i ē t hē H K t E ha ē
H K t E ha ē	hē t E ha ē H K Li i ē
H a hē har a	Jia H a hē har a ē i al C ., Lj .*(江蘇黃河藥業股份有限公司), i 𐄂 ē t hr h ē i t r a ē r i Ja ar 2022
H K	t hē H K 𐄂 i al A i i r a i vē ē i t hē C
IN	𐄂𐄂 , hē la l r ē l i a

Definitions

I ₁ i i v e F HK	I ₁ i i v e r i a l-F (H) C ., Li i e , a a i e i e i H K a
I ₁ i i v e F ha hai	I ₁ i i v e r i a l-F M e i a l e h l (ha hai) C ., L .* (直觀復星醫療器械技術(上海)有限公司), a a i a e h e C
I ₁ i i v e F	I ₁ i i v e F HK a I ₁ i i v e F ha hai
K i e h a r a	K E C. , a a i e i e i h e N e h a
Ma a	h e Ma a i a l A i i i a i v e e i h e C
M e	ME CK HA & D HME C ., a a i e i e i h e i e i a e
M e l C e	

ha hai t E ha e	t h e ha hai t E ha e (上海證券交易所)
ha hai ra i	ha hai ra i e h l C ., L .* (上海輸血技術有限公司), i h e t hr h e i t ra e i E e r ar 2022
ha e h l e t ()	h l e t () ha e
ha e	r i ar ha e i t h e a j al t h e C a i h a i al al e MB1.00 e a h, i i A ha e a H ha e
h e h e t E ha e	t h e h e h e t E ha e (深圳證券交易所)
i har H al h li e	i har H al h li e C ., L .* (國藥健康在線有限公司)
i har l t rial	i har l t rial l v e t e t C ., L .* (國藥產業投資有限公司), a a i a e t h e C a
i har	i har Gr C . L .* (國藥控股股份有限公司), a a h e H ha e a e li e h e H K t E ha e (t e: 01099) a a i ar i har l t rial
i ra M e i al	i ra M e i al L , a i ar t h e C a , t h e ha e hi h a e li e t h e H K t E ha e (t e: 01696)
h j r	t h e e e t t h e h j r C i e e
h j r C i e e	t h e h j r i e e t h e C a
h A a a	h A a a M e i al e h l C ., L .* (蘇州百道醫療科技有限公司), a i ar t h e C a
ia ji Xi i i	ia ji Xi i i Bi e h l C ., L .* (天津星絲奕生物科技有限公司)
. FDA	. F a Dr A i i t a i
. r i e t a e	i e a e A e i a, i e r i i e a h e i , a t a e t h e i e t a e a t h e Di t t C l ia
llar r \$	i e t a e llar , t h e la l r e t h e i e t a e
i har Gr C . L .3EA.* (EAC051E1 2B7 00 a i i Bi e h l C ., ha OEE B0102CB0D15EB0F8708700D86_0 1(

Definitions

Xi hi H ɿ al	G a ɿ h Xi hi H ɿ al C ., L ɿ .* (廣州新市醫院有限公司) (h ɛ h ɪr A ɪ li a ɿ ɛ H ɿ al G a ɿ har a ɛ i al ɿ ɿ ɿ i ɿ * (廣東藥科大學附屬第三醫院)), a ɿ i ar ɿ h ɛ C ɿ a a ɿ h ɛ ɛ ɿ h ɛ ɛ ɿ i ɿ ɛ ɿ
X ɿ h ɛ h i	X ɿ h ɛ h i har a ɛ i al ɿ ail C ., L ɿ .* (徐州風友匯藥品零售有限公司), ɛ ɛ i ɛ ɛ i ɛ ɛ ɿ ar 2022
ɿ ɛ Bi ɿ h	ɿ ɛ Bi ɿ h l (h ɛ ɿ h ɛ) C ., L ɿ .* (亞能生物技術(深圳)有限公司)
ɿ har a	Ch ɿ i ɿ har a ɛ i al C ɿ Li i ɿ * (重慶藥友製藥有限責任公司), a i ar ɿ h ɛ C ɿ
l hi ɛ ɿ i h ɛ i a i i ɛ ɛ h ɛ Chi ɛ ɛ a ɛ h ɛ i ɛ , a h ɿ i ɛ , ɿ a i a i , i i i i ɿ ɛ ɛ ɿ i ɛ ɛ a li h ɛ i Chi a ɿ h ɛ a ar ɿ ɿ i a ɛ i ɛ i Chi a a ɿ h ɿ E ɿ li h ɿ la i , ɿ h ɛ Chi ɛ ɛ ɿ i hall ɿ ail.	
* F ɿ i ɛ i a i ɿ ɿ ɛ l	